 cryoprotection agent and its use, cryoprotection compositions and method for cryopreserving sample &
专利摘要:
abstract patent of invention: "cryoprotection agent, cryoprotection and cryopreserved compositions, uses of them and methods of cryopreservation". the present invention relates to a cryoprotection agent that comprises a cryoprotectant which is one or more of: dextrin, dextran, isomalto-oligosaccharide and derivatives thereof, cryoprotection and cryopreserved compositions, uses of the same and methods of cryopreservation. 公开号:BR112015012161B1 申请号:R112015012161 申请日:2013-11-29 公开日:2020-05-05 发明作者:Holst Björn；Clausen Christian；Berg Andreasen Hans；Skytte Jeppe；Nordfjeld Kim；Christensen Lars 申请人:Pharmacosmos As； IPC主号:
专利说明:
Descriptive Report of the Invention Patent for CRYPROTECTION AGENT AND ITS USE, CRYPROTECTION COMPOSITIONS AND METHOD FOR CRYOPRESERVING SAMPLE. Field of the Invention [0001] The present invention relates to a cryoprotectant, a cryoprotective agent, cryoprotection compositions, cryopreserved compositions, uses thereof and methods of cryopreservation. Background of the Invention [0002] The cryopreservation of viable biological samples, such as cells, tissues or organs, which were collected from a donor source, is of great importance and usefulness in the scientific and medical communities. Cryopreservation is generally a process in which a sample, for example, cells or tissue, is preserved by cooling to below zero temperatures, typically 77 K (= -196 ° C, the boiling point of liquid nitrogen). At these low temperatures, any biological activity, which includes the biochemical reactions that would cause the cell to die, is effectively stopped. Cryopreservation techniques are commonly used for long-term preservation of aqueous or water-containing materials, such as cells and tissues of plants and animals. It is known that, when these materials are frozen, ice crystals are formed, resulting in irregular concentrations of solutes and contaminants excluded by water molecules, called freezing concentration. In order for cells or tissues to be preserved, cryoprotective solutions are typically used to prevent damage due to freezing during the cooling or thawing process. For cryopreservation to be useful, the preserved sample should maintain its integrity and viability at a reasonable level in the time of collection. Thus, the process of preserving the sample should not, Petition 870160070045, of 11/24/2016, p. 5/15 2/75 preferably, alone, severely damage or destroy, for example, cells or tissue architecture. [0003] In conventional cryopreservation techniques, the sample is collected, placed in a storage solution and then preserved by freezing. When the sample is to be used, it is thawed and, for example, cells taken from human donor sources are returned to normal human body temperature (ie approximately 37 ° C) and then placed in a cell culture medium. Cryopreservation protocols subject cells to a great deal of stress and aggression throughout the process of cell collection, freezing and thawing. These stresses and assaults can cause irreversible damage to the cell. [0004] Dextran has been used as a cryoprotective agent for cells in plants, animals and humans (Odavic, R. et al. Experientia 36, 1122 (1980), Ashwood-Smith, MJ et al. Cryobiology 9, 441 ( 1972) and Echlin, P. et al. J. Microsc. (Oxford) 110, 239 (1977)). A mixture of 5% methyl sulfoxide and 9% dextran 70 has been found to provide optimal cryoprotection of compromised human bone marrow stem cells (Dextran, Handbook from Amersham BioSciences, 18-1166-12, Edition AA, page 35 ). Dextran, glycerol and dimethyl sulfoxide (DMSO), alone or in combination, have been investigated for the cryoprotection of human bone marrow cells (Odavic, R. et al. Experientia 36, 1122 (1980)). Significantly better protection against freezing injury was achieved with 9% Dextran 70 in combination with 3 or 5% DMSO, and also with 5 or 10% DMSO alone, than with 15% glycerol or 9% dextran with 1% DMSO. Dextran 40 is known (Proc. Nati. Acad. Sci. USA, Vol. 92, pages 10,119 to 10,122, October 1995, Medical Sciences) for the cryopreservation of 3/75 umbilical cord / placental blood in a combination of 50% DMSO in 5% (weight by volume) Dextran 40. [0005] Shu Guowei et al. describe, in Advanced Materials Research, Trans Tech Publications Ltd., Vol. 328 (2012), pages 454 to 457, the effect of fructo-oligosaccharide, isomalto-oligosaccharide, inulin and xylooligosaccharide on the survival of B. bifidium during freeze drying. Kwan Hwa Park et al. In Database CA, XP 002698458, they describe a cryoprotectant that contains fructooligosaccharides, isomalto-oligosaccharides or galacto-oligosaccharides for surimi. In J. Korean Soc. Food Sci. Nutr., Vol. 30 (3) (2001), pages 565 to 568, the effects of a frito-oligosaccharide, isomalto-oligosaccharide and galacto-oligosaccharide cryoprotectant on beef protein are described . [0006] Conventional cryoprotectants are glycols (alcohols containing at least two hydroxyl groups), such as ethylene glycol, propylene glycol and glycerol. Ethylene glycol is commonly used as a car antifreeze, and propylene glycol has been used to reduce ice formation in ice cream. Dimethyl sulfoxide (DMSO) is also considered to be a conventional cryoprotectant. Glycerol and DMSO have been used for decades by cryobiologists to reduce the formation of ice in sperm and embryos that are preserved in liquid nitrogen (-196 ° C). Among these known cryoprotective agents, DMSO is considered to be the most effective and is often adopted, but it is physiologically toxic and known to cause high blood pressure, nausea and vomiting if transfused into a recipient with the cells or in whom it is handled, except when precautions are taken. Cox et al. (Cell Tissue Bank (2012) 13: 203 to 215) identified, through a retrospective analysis of published literature, several hundred adverse reactions (for example, nausea, chills, cardiac arrhythmias, neurological symptoms and arrest 4/75 respiratory) associated with the transplantation of cryopreserved stem cells with dimethyl sulfoxide. In addition, DMSO toxicity tends to weaken cell functions and / or survival rates, which include genomic changes after thawed cells are cultured or transfused into a recipient's body. DMSO toxicity, therefore, also affects the amount of time that cells can be exposed to DMSO during handling. [0007] Thus, there is still a need for a cryoprotectant to protect a sample, such as a biological sample, during freezing as a replacement for other cryoprotectants, such as DMSO, or as a supplement for such other cryoprotectants, for reduce the necessary concentration of the same, preferably to non-toxic concentrations, which, at the same time, has the necessary protective effects and low toxicity. Objective of the Invention [0008] It is an objective of the modalities of the invention to provide a cryoprotectant as a replacement for other cryoprotectants, such as DMSO, or as a supplement to such other cryoprotectants, to reduce their concentration, preferably to non-toxic concentrations , whose cryoprotectant has the necessary protective effects in terms of preserving as much of the cryopreserved functionality as possible during cryopreservation. It is an additional objective of the modalities of the invention to provide a cryoprotectant that has a low toxicity for those who transport the cryoprotectant and for biological samples, so that the time that the sample can stay in contact with the cryoprotectant without being damaged is prolonged, the need for washing samples is reduced and, preferably, if desired, allowing the return of the sample to where it was taken or to recipient without having to separate the sample 5/75 from the cryoprotectant. It is a further object of the modalities of the invention to provide a cryoprotectant that is effective as a cryoprotectant for a sample selected from the group consisting of organs, cells and tissues, as selected from the group consisting of mammalian organs, cells of mammal and mammalian tissues. It is a further object of the modalities of the invention to provide a cryoprotectant that is effective as a cryoprotectant for a sample to be transplanted, such as an organ, cells or tissue. It is a further object of the embodiments of the invention to provide a cryoprotectant that is effective as a cryoprotectant of, for example, cells and results in an acceptable viability of said cells. It is an additional object of the modalities of the invention to provide a cryoprotectant that is effective as a cryoprotectant of, for example, organs and results in an acceptable physical functionality of said organs. It is a further object of the modalities of the invention to provide a cryoprotectant that is effective as a cryoprotectant of, for example, tissues and results in an acceptable physical functionality of said tissues. Summary of the Invention [0009] The present inventor (s) have found that a cryoprotectant agent comprising one or more cryoprotectants selected from the group consisting of dextrin, dextran, isomalto-oligosaccharide, and derived therefrom, and a) in which said cryoprotection agent comprises at least 1% by weight of one or more among isomalto-oligosaccharides and derivatives thereof having a weight average molecular weight (M w ) between 300 and 1,650 Da with based on the total weight of dextrin, dextran, isomaltooligosaccharide, and derivatives thereof in said agent, or b) wherein said cryoprotectant has a weight average molecular weight (Mw) between 300 and 9,500 Da, such as between 300 and 7,500 Da, or c) wherein said cryoprotection agent comprises at least 1% by weight of 6/75 one or more among isomalto-oligosaccharides and derivatives thereof having a weight average molecular weight (M w ) between 300 and 1,650 Da, based on the total weight of dextrin, dextran, isomaltooligosaccharide and derivatives thereof in said agent, and said cryoprotectant has a weight average molecular weight (Mw) between 300 and 9,500 Da, is very useful as a cryoprotectant. In comparison to previously used higher molecular weight dextran materials, such as Dextran 40 (40,000 Da) and Dextran 70 (70,000 Da), the cryoprotectant comprising the cryoprotectant described above has a lower viscosity due to the lower molecular weight and it can thus be pre-prepared in a high concentration, making it possible to add a sample to a solution and still obtain a composition that comprises both cryoprotectant and sample in a concentration suitable for cryopreservation. In addition, molecules with lower molecular weight are generally less immunogenic than molecules with high molecular weight. Dextran 1 is known as a hapten inhibitor that reduces the risk of anaphylactic reactions when dextran is administered and is therefore used as a pre-injection before the injection of higher molecular weight dextrans, such as Dextran 40 (40,000 Da) and Dextran 70 (70,000 Da). Dextran 1 has also been documented in studies by Richter et al. (Int. Arch. Allergy 43: 252 to 268 (1972) and Int. Arch. Allergy 41: 826 to 844 (1971)) as having very low immunological potential in humans. In addition, it has been shown in the examples that cryopreservation with the cryoprotectant, as described in this document, provides better protection of functionality after cryopreservation, measured as the viability of the cells tested, than with dextrans with a higher molecular weight. [0010] Thus, in a first aspect, the present invention refers to 7/75 refers to a cryoprotection agent comprising one or more cryoprotectants selected from the group consisting of dextrin, dextran, isomalto-oligosaccharide and derivatives thereof, and a) in which said cryoprotection agent comprises at least 1% by weight of one or more among isomalto-oligosaccharides and derivatives thereof having a weight average molecular weight (Mw) between 300 and 1,650 Da based on the total weight of dextrin , dextran, isomalto-oligosaccharide, and derivatives thereof, or b) in which said cryoprotectant has an average molecular weight (M w ) between 300 and 9,500 Da, such as between 300 and 7,500 Da or, c) wherein said cryoprotection agent comprises at least 1% by weight of one or more among isomalto-oligosaccharides and derivatives thereof having a weight average molecular weight (Mw) between 300 and 1,650 Da based on the total weight of dextrin , dextran, isomalto-oligosaccharide and derivatives thereof in said cryoprotectant, and said cryoprotectant has a weight average molecular weight (Mw) between 300 and 9,500 Da. [0011] In a further aspect, the present invention relates to a cryoprotection agent that comprises a cryoprotectant selected from the group consisting of isomalto-oligosaccharide and derivatives thereof that has a weight average molecular weight (Mw) between 300 and 1,650 Da, such as between 850 and 1,650 Da. [0012] In a further aspect, the present invention relates to the use of a cryoprotectant, as described in the present document, to cryopreserve a sample, in which said sample is selected from the group consisting of organs, cells and tissues. [0013] In a further aspect, the present invention relates to a cryopreservation composition comprising a cryoprotection agent, as described herein, such cryopreservation composition further comprises a sample to be 8/75 be cryopreserved, in which said sample is selected from the group consisting of organs, cells and tissues. [0014] In a further aspect, the present invention relates to a cryopreserved composition comprising a cryoprotective agent, as described in the present document, such cryopreserved composition further comprises a sample that has been cryopreserved, wherein said sample is selected from the group consisting of organs, cells and tissues. [0015] In a further aspect, the present invention relates to a method for cryopreserving a sample, which comprises the steps of placing a sample to be cryopreserved in contact with a cryoprotective agent, as described in this document, to obtain a composition cryopreservation and subsequently reduce the temperature of the cryopreservation composition to a cryopreservation temperature, in which said sample is selected from the group consisting of organs, cells and tissues. [0016] In a further aspect, the present invention relates to a method for cryopreserving a cryopreservation composition, as described in the present document, by placing the composition at a cryopreservation temperature. [0017] In a further aspect, the present invention relates to the use of a cryoprotection agent, as described in this document, to cryopreserve a sample, in which said sample is selected from the group consisting of organs, cells and fabrics. [0018] In a further aspect, the present invention relates to the use of a cryoprotection agent, as described in this document, to cryopreserve a sample for transplantation. [0019] In a further aspect, the present invention relates to the use of a cryopreservation composition, as described in 9/75 this document, to cryopreserve a sample by reducing the temperature of said composition to a temperature of cryopreservation, in which said sample is selected from the group consisting of organs, cells and tissue. Legends to figure [0020] Figure 1 shows the survival NHDFs after thaw and viability after 1 passage in, respectively, 1) 10% DMSO, 2) 8% isomalto-oligosaccharide 1 (ISOM) and 2% DMSO, 3) 8% isomalto-oligosaccharide 1 (ISOM) and 4) DMEM, as described in Example 2. [0021] Figure 2 shows the survival of NHDFs after thawing and viability after 1st pass in, respectively, 1) 10% DMSO, 2) 8% hydrogenated isomalto-oligosaccharide 1 (H-ISOM) and 2% of DMSO, 3) 8% hydrogenated isomalto-oligosaccharide 1 (H-ISOM) and 4) DMEM, as described in Example 2. [0022] Figure 3 shows the survival of NHEKs after thawing and viability after the 1st pass in, respectively, 1) 10% DMSO, 2) 8% isomalto-oligosaccharide 1 (ISOM) and 2% DMSO, 3) 8% isomalto-oligosaccharide 1 (ISOM) and 4) DMEM, as described in Example 3. [0023] Figure 4 shows the survival of NHEKs after thawing in respectively 1) 10% DMSO, 2) 8% hydrogenated isomalto-oligosaccharide 1 (H-ISOM) and 2% DMSO, 3) 8% isomalt -hydrogenated oligosaccharide 1 (H-ISOM) and 4) DMEM, as described in Example 3. [0024] Figure 5 shows the survival of MSCs after thawing and viability after the 1st pass in, respectively, 1) 10% DMSO, 2) 8% isomalto-oligosaccharide 1 (ISOM) and 2% DMSO, 3) 8% hydrogenated isomalto-oligosaccharide 1 (HISOM) and 2% DMSO, 4) 8% isomalto-oligosaccharide 1 (ISOM), 10/75 5) 8% hydrogenated isomalto-oligosaccharide 1 (H-ISOM) and 6) DMEM, as described in Example 4. [0025] Figure 6 shows the survival of human iPS cells in PluriPro growth medium after thawing and cryopreservation in, respectively, Growth medium + 10% DMSO, Growth medium + 5% DMSO, Growth medium + 10 % DMSO + 2% isomalto-oligosaccharide 1 (ISOM), Growth medium + 10% DMSO + 4% isomalto-oligosaccharide 1 (ISOM), Growth medium + 10% DMSO + 8% isomaltooligosaccharide 1 ( ISOM), Growth medium + 5% DMSO + 2% isomalto-oligosaccharide 1 (ISOM), Growth medium + 5% DMSO + 4% isomalto-oligosaccharide 1 (ISOM), Growth medium + 5% DMSO + 8% isomalto-oligosaccharide 1 (ISOM), Growth medium + 2% isomalto-oligosaccharide 1 (ISOM), Growth medium + 4% isomalto-oligosaccharide 1 (ISOM), Growth medium + 8% isomalto-oligosaccharide 1 (ISOM), and Growth medium, without any cryoprotectant, as described in Example 7. [0026] Figure 7 shows the survival of human iPS cells in PluriPro growth medium after thawing and cryopreservation in, respectively, Growth medium + 10% DMSO, Growth medium + 5% DMSO, Growth medium + 10 % DMSO + 2% hydrogenated isomalto-oligosaccharide 1 (H-ISOM), Growth medium + 10% DMSO + 4% hydrogenated isomaltooligosaccharide 1 (H-ISOM), Growth medium + 10% DMSO + 8% hydrogenated isomalto-oligosaccharide 1 (H-ISOM), growth medium + 5% DMSO + 2% hydrogenated isomaltooligosaccharide 1 (H-ISOM), growth medium + 5% DMSO + 4% hydrogenated isomalto-oligosaccharide 1 (H-ISOM), Growth medium + 5% DMSO + 8% isomalt 11/75 hydrogenated oligosaccharide 1 (H-ISOM), Growth medium + 2% hydrogenated isomalto-oligosaccharide 1 (H-ISOM), Growth medium + 4% hydrogenated isomalto-oligosaccharide 1 (H-ISOM), growth + 8% hydrogenated isomalto-oligosaccharide 1 (H-ISOM) and growth medium without any cryoprotectant, as described in Example 8. [0027] Figure 8 shows the survival of MSCs after thawing and proliferation after 3 days in, respectively, 1) 10% DMSO, 2) CRYO, which designates 8% isomalto-oligosaccharide 1, Dextran Mw 10,000 or Dextran Mw 40,000, respectively, Each combined with 5% DMSO, 3) CRYO, which designates 8% isomalto-oligosaccharide 1, Dextran Mw 10,000 or Dextran Mw 40,000, respectively, each combined with 1% DMSO, 4) CRYO, which designates 8% isomalto-oligosaccharide 1, Dextran Mw 10,000 or Dextran Mw 40,000, respectively, and 5) DMEM, as further described in Example 9. [0028] Figure 9 shows the survival of MSCs after thawing in, respectively, 1) 10% DMSO, 2) 2% DMSO, 3) 8% isomalto-oligosaccharide Mw 1,500 (ISOM) and 2% DMSO , 4) 8% isomalto-oligosaccharide Mw 1,500 (ISOM) and 5) DMEM, as further described in Example 10. [0029] Figure 10 shows the viability of CD34 + hematopoietic stem cell after cryopreservation with DMSO, hydrogenated isomaltooligosaccharide 1 or hydrogenated isomalto-oligosaccharide 1, as further described in Example 11. [0030] Figure 11 shows the viability of adipose-derived stem / stromal cells (ASC's) after cryopreservation with DMSO, hydrogenated isomalto-oligosaccharide 1 or hydrogenated isomalto-oligosaccharide 1, as further described in Example 12. 12/75 Detailed Description of the Invention Definitions [0031] As used in the present invention, cryopreservation refers to a process in which a sample is preserved by cooling to below freezing temperatures, which includes vitrification technology, in which the cooling rate is faster than a procedure conventional cryopreservation. At such low temperatures, activity, such as biological activity, which includes biochemical reactions that would cause, for example, cell death, is reduced, and the chemical structure / function of, for example, proteins / glycoproteins or lipoproteins is preserved. If cryoprotectant solutions are not used, samples that are preserved are prone to damage due to freezing during the cooling or thawing process. [0032] In a preferred aspect, cryopreservation refers to a process in which samples are preserved by cooling to temperatures below zero, typically 77 K (= -196 ° C, the boiling point of liquid nitrogen). At these low temperatures, any biological activity, which includes biochemical reactions that would cause cell death, is effectively stopped. [0033] For use in the present invention, the term cryopreservation temperature designates a temperature from below zero to -196 ° C, such as from - 50 ° C to -196 ° C, such as from 80 ° C to -196 ° C, such as below -55 ° C, below -60 ° C, below -65 ° C, below -70 ° C, below -75 ° C, such as below -80 ° C, as below -85 ° C, as below -90 ° C, as below -95 ° C, as below -100 ° C , such as below -105 ° C, such as below 110 ° C, as below -115 ° C, as below -120 ° C, as below -125 ° C, as below - 130 ° C, as below 13/75 135 ° C, such as below -140 ° C, as below -145 ° C, as below -150 ° C, as below -155 ° C, as below 160 ° C, such as below -165 ° C, as below -170 ° C, as below -175 ° C, as below -180 ° C, as below 185 ° C, as below -190 ° C . [0034] As used in the present invention, the term sample refers to any type of material to be cryopreserved, such as organs, cells or tissue. In one aspect, a sample is selected from the group consisting of organs, cells, tissue and blood. In one aspect, a sample is selected from the group consisting of organs, cells and tissue, as selected from the group consisting of mammalian organs, mammalian cells and mammalian tissues. In one aspect, the term sample does not include the human body at the various stages of its formation and development. In a further aspect, the present invention relates to the use of a cryoprotection agent, as described herein, to cryopreserve a sample for transplantation. In one aspect, the sample is selected from the group consisting of mammalian organs, mammalian cells and mammalian tissues for transplantation. [0035] For use in the present invention, the term cells comprise any type of cells, such as somatic cells, which include all types of cells in tissue or organs, stem cells which include all types of totipotent stem cells, cells - pluripotent stem, multipotent stem cells and progenitor cells; oocytes; sperm; and germ cells. The cells can be in isolated form or in a non-isolated form, such as in the form of a body fluid containing cell, tissue or organ. [0036] For use in the present invention, the term cell-containing body fluids includes any cell-containing body fluid, 14/75 such as, for example, blood defined below, amniotic fluid, semen, cerebrospinal fluid, bone marrow aspirates and menstrual fluid. [0037] For use in the present invention, the term blood comprises any fluid containing blood, such as umbilical cord blood, peripheral blood and mobilized blood. [0038] For use in the present invention, the term tissue or tissues comprises any type of tissue comprising any type of cell and combinations thereof, which includes ovarian tissue, testicular tissue, umbilical cord tissue, placental tissue, connective tissue, cardiac tissue, tissue from muscle, cartilage and bone, endocrine tissue and neural tissue. The term tissue or tissues also includes adipose tissue or dental pulp tissue. [0039] For use in the present invention, the term organ includes, for example, lung, liver, kidney, heart, ovaries and pancreas. The term organ also includes umbilical cord. [0040] For use in the present invention, the term functional after cryopreservation in relation to a sample means that the sample, such as organs, tissue or cells, after cryopreservation retains an acceptable and / or desired function after cryopreservation. In one aspect, the sample after cryopreservation retains its full function. In another aspect, the sample, such as cells, retains at least 50% of the desired function, such as at least 60% of the desired function, such as at least 70% of the desired function, such as at least 80% of the desired function , such as at least 90% of the desired function, such as at least 95% of the desired function, such as 100% of the desired function. As an example in relation to cells, an important function to be preserved is the viability of the cells. As another example in relation to organs, an important function to be preserved is the physiological function of such an organ, for example, for a heart the pumping function. 15/75 As another example in relation to tissue, an important function to be preserved is the ability of such tissue to integrate with the surrounding tissue (for example, skin) in the case of transplantation. [0041] The viability of cells after cryopreservation can be measured using the Nucleocounter system, in which dead cells are measured by incubating the cell sample with DNA-binding dye, propidium iodide, which only results in detectable measurement from dead cells, as shown in the examples. Viability is given as a percentage of living cells in the population being analyzed. The proliferative rate of a cell sample after cryopreservation can be analyzed using the colorimetric assay, MTT. [0042] As used in the present invention, the term bank refers to any storage of a sample for future use. [0043] As used in the present invention, the term clinical bank method refers to any storage of a sample in relation to the clinical treatment of a mammal, such as a human. [0044] As used in the present invention, the term marrow bank method refers to the storage of a marrow sample, such as bone marrow aspirates and related body fluid, or cells isolated from the marrow. [0045] As used in the present invention, the term dental pulp tissue bank method refers to the storage of a dental pulp tissue sample, such as cells isolated from dental pulp tissue. [0046] As used in the present invention, the term adipose tissue bank method refers to the storage of a sample of adipose tissue, such as cells isolated from adipose tissue. In the present context, the term and the continuation, ban method 16/75 umbilical cord co refers to the storage of umbilical cord blood, tissues related to the umbilical cord, or cells isolated from the umbilical cord blood or tissue. [0047] In the present context, the term and in the following, mobilized peripheral blood bank method refers to the storage of peripheral blood after mobilization with agents that, for example, releases stem cells from the blood into the circulation. [0048] As used in the present invention, the term breeding bank method refers to the storage of any sample related to reproduction, such as semen, oocytes, sperm, fertilized eggs, etc. [0049] The Dalton atomic mass unit (symbol: Da) is the standard unit used to indicate mass on an atomic or molecular scale (atomic mass). It is defined as a twelfth part of the remaining mass of a neutral carbon-bound atom12 in its electronic and nuclear fundamental state. [0050] As used in the present invention, the term weight average molecular weight (M w ) is defined as: l = p Σ gl M l M w = = h - Σ gi i = 1 where gi is the fraction of molecules with the molecular weight Mi. The possible values of M make up a set of numbers with distinct values identified with Mi, defining p. [0051] For use in the present invention, the term numerical average molecular weight is defined as: i = p Σ (g, / M,) M, Σ NiM M = ^ -------- = ú = 1 --- n i = pi = p X (gi / Mi) ΣΝ i = 1i = 1 17/75 where N, is the fraction of molecules with the molecular weight Μ ,, gi is the fraction of molecules with the molecular weight μ ,. The possible values of M make up a set of numbers with distinct values identified with μ ,, defining p. [0052] As used in the present invention, the term polydispersion (Pd) is calculated by M w / M n = Pd. [0053] As used in the present invention, the term Dextran followed by a number, such as Dextran 1, Dextran 40 and Dextran 70 follows the abbreviation of the pharmacopoeia for Dextran X, which means that the weight average molecular weight of dextran is approximately X kDA. Thus, Dextran 1 refers to a dextran that has a weight average molecular weight of 850 to 1,150 Da. Isomalto-oligosaccharide 1, and hydrogenated isomalto-oligosaccharide 1 are similarly named. Isomalto-oligosaccharide 1 thus refers to a mixture of isomalto-oligosaccharides that have a weight average molecular weight of 850 to 1,150 Da according to the EP and USP monographs for Dextran 1. Isomaltooligosaccharide 1 is also called pentaisomaltose in this application. Hydrogenated isomalto-oligosaccharide 1 refers to a mixture of hydrogenated isomalto-oligosaccharides, in which the isomaltooligosaccharides are in accordance with the EP and USP monographs for Dextran 1. Hydrogenated isomalto-oligosaccharide 1 is also called penta-isomaltoside in the present application. [0054] As used in the present invention, the term dextran-based isomaltooligosaccharide refers to an isomaltooligosaccharide that has a weight average molecular weight (Mw) between 300 and 1,650 Da, such as between 850 and 1,650 Da, and obtained from hydrolyzed dextran, such as by means of low molecular weight dextran hydrolysis. [0055] As used in the present invention, the term cryoprote 18/75 tor refers to a substance that, for example, in a suitable solution is used to protect a sample from freezing damage. Examples of known cryoprotectants are, for example, DMSO, polyols, etc. [0056] As used in the present invention, the term sterile means free of germs, living microorganisms and other organisms capable of proliferation. [0057] As used in the present invention, the term substantially free of DMSO refers to DMSO in an amount less than 0.01% by weight. [0058] As used in the present invention, C 1-10 alkyl is a hydrocarbon that is straight or branched chain C 1-10 alkyl, such as straight or branched chain C 1-6 alkyl. Examples are methyl, ethyl, 1-propyl, 2-propyl, isopropyl, 1-butyl, 2-methyl-1propyl, 2-butyl, 1-pentyl, 3-pentyl, 2-methyl-2-butyl and 3-methyl -2-butyl. [0059] As used in the present invention, carboxy C 1-10 alkyl refers to C 1-10 alkyl -COOH. An example is carboxymethyl (CM) (-CH2COOH). [0060] For use in the present invention, the term DEAE refers to diethylaminoethyl. Cryoprotectant [0061] A cryoprotectant comprising a cryoprotectant which is one or more selected from the group consisting of dextrin, dextran, isomaltooligosaccharide and derivatives thereof is described in this document and a) wherein said cryoprotection agent comprises at least 1% by weight of one or more among isomalto-oligosaccharides and derivatives thereof having a weight average molecular weight (Mw) between 300 and 1,650 Da, as well as an average molecular weight weight (Mw) between 850 and 1,650 Da based on the total weight of dextrin, dextra 19/75 no, isomalto-oligosaccharide and derivatives thereof in said cryoprotection agent, or b) in which said cryoprotectant has an average molecular weight (M w ) between 300 and 9,500 Da, such as between 300 and 7,500 Da, or c) wherein said cryoprotection agent comprises at least 1% by weight of one or more among isomalto-oligosaccharides and derivatives thereof having a weight average molecular weight (M w ) between 300 and 1,650 Da, such as between 850 and 1,650 Da based on the total weight of dextrin, dextran, isomalto-oligosaccharide and derivatives thereof in said cryoprotection agent, and said cryoprotectant has a weight average molecular weight (M w ) between 300 and 9,500 Da. [0062] In one aspect, said cryoprotectant is selected from the group consisting of dextran, isomalto-oligosaccharide and derivatives thereof. [0063] The molecular weight of dextran and dextrin, and / or a derivative thereof, is typically determined by means of gel permeation chromatography (GPC) using, for example, hydroxylated polyether GPC columns. The calibration may be performed as described in the European Pharmacopoeia, edition 7, to dextran and the repetitive use of the mathematical method, as described in the European Pharmacopoeia, 7th edition, volume 2, pages 1816-1817, to dextran. [0064] The molecular weight of isomalto-oligosaccharide and / or a derivative thereof, such as hydrogenated isomalto-oligosaccharide, is typically determined by means of gel permeation chromatography (GPC). The stationary phase in the column system can be dextran covalently linked to highly cross-linked porous agarose microspheres, allowing the resolution of oligosaccharides in the molecular mass range of 180 to 3,000 Da. The measurement is made according to the European Pharmacopoeia, 7th edition, volume 1, pages 60 to 61. 20/75 [0065] When said cryoprotectant is electrically neutral, the average molecular weight (M w ) of said cryoprotectant is preferably measured by GPC. When measuring the average molecular weight (Mw) of a cryoprotectant carrying an electrical charge, the average molecular weight (Mw) is calculated based on the molecular weight of the electrically neutral starting material, and the degree of substitution of the charged cryoprotectant . Each unit of glucose in the unloaded starting material can be replaced with between 1 and 3 substituents. Using DEAE as an example of a substituent, the person skilled in the art can measure, for example, the nitrogen content (for example, using Kjeldahl analysis) to calculate the degree of substitution and then calculate the weight of the final product. If the substituent contains an acidic group, the degree of substitution can be determined, for example, by the element skilled in the art by means of titration and, subsequently, the final molecular weight can be calculated. [0066] Dextrin, dextran and isomalto-oligosaccharide comprise repeating D-glucose units. Dextrans are a family of neutral branched polysaccharides that predominantly consist of a- (1 ^ 6)-linked D-glucose, as further described below. Dextrins are mixtures of polymers of D-glucose units linked by glycosidic bonds a- (1 ^ 4) or a- (1 ^ 6), as further described below. Isomalto-oligosaccharide is a mixture of glucose oligomers with aD- (1,6) bonds (typically less than 10 units of D-glucose, suitably between 3 to 6 units of glucose) and typically has an average molecular weight between 300 and 1,650 Da, such as between 500 and 1,650 Da, such as between 850 and 1,650 Da, or as between 850 Da and 1,150 Da. In one aspect, the weight fraction of isomalto-oligosaccharides that have less than 3 units of glucose is less than 15% by weight. In one the 21/75 pecto, the weight fraction of isomalto-oligosaccharides having more than 9 glucose units is less than 20% by weight, such as less than 15% by weight, such as less than 10% by weight. In an additional aspect, the isomalto-oligosaccharide weight fraction that has less than 3 glucose units is less than 15% by weight and the isomalto-oligosaccharide weight fraction that has more than 9 glucose units is less than 20% by weight, such as less than 15% by weight, such as less than 10% by weight. The weight fraction can, for example, be determined as described in Preparation Example 1 and 2 herein. [0067] In one aspect, a dextrin, dextran and isomalto-oligosaccharide derivative are selected from the group consisting of hydrogenated isomalto-oligosaccharide, hydrogenated dextran, hydrogenated dextrin, oxidized isomalto-oligosaccharide, oxidized dextrin, oxidized, dextrin is oxidized, dextrin is oxidized, dextrin, dextran ester, isomalto-oligosaccharide ester, dextrin ether, dextran ether, isomalto-oligosaccharide ether and partially hydrogenated / oxidized dextran, partially hydrogenated / oxidized and isomaltooligosaccharide, partially hydrogenated and oxidized dextran and the same partially hydrogenated oxides and partially hydrogenated oxides. In one aspect, an isomalto-oligosaccharide derivative is selected from the group consisting of hydrogenated isomaltooligosaccharide, oxidized isomalto-oligosaccharide, isomalto-oligosaccharide ester, isomalto-oligosaccharide ether, and isomalto-oligosaccharide derivatives and is partially oligosaccharide / oligosaccharide themselves. [0068] Below is a schematic overview (Table A) of examples of the different syntheses and starting materials for the dextrin, dextran and isomaltooligosaccharide derivatives described above: 22/75 TABLE A: Starting material / Overview Hydrogenation Oxidizeddog* Esterification Etherification Dextran X X X X Isomalto-oligosaccharides X X X X Dextrin X X X X Hydrogenated dextranX X X Hydrogenated isomalto-oligosaccharidesX X X Hydrogenated dextrinX X X Oxidized dextran XX X Oxidized isomalto-oligosaccharides XX X Oxidized dextrin XX X * In one aspect, the synthesis may be a method of partial oxidation and hydrogenation to obtain hydrogenated and partially oxidized derivatives, e.g., as described in the document under n. US 6,977,249 [0069] In one aspect, the type of said dextrin ether, dextran ether and isomalto-oligosaccharide ether is selected from the group consisting of ethers that has a functional group R. R is selected from of the group consisting of C 1-10 alkyl, such as C 1-6 alkyl, such as methyl (-CH3) andethyl (-C 2 H 5 ), C 1-10 carboxyalkyl, such as carboxymethyl (-CH2COOH), hydroxyalkyl C 1-10 , such as 2hydroxyethyl (-C2H4OH), 2-hydroxypropyl (-CH2CHOHCH3), 2hydroxyalkyl (-CH2CHOH (CH2) nCH3, where n is 1 to 10), 3-chloro-2hydroxypropyl (-CH2CHOHCH2Cl), 2 -diethylaminoethyl (-C2H4N (C2H5) 2), 3 amino-2-hydroxypropyl (-CH2CHOHCH2NH2), 3-dimethylalkylammonium-2hydroxypropyl (-CH2CHOHCH2N + (CH3) 2R, where R is C1-10 alkyl), polyethylene, polyethylene 2 CH 2 O) 10 C 16 H33), and stearyl polyethylene glycol (-CH 2 CH 2 O) ( 10 Cl 8 H 37). [0070] In one aspect, said dextrin ether, dextran ether and isomalto-oligosaccharide ether are DEAE-dextrin, DEAE-dextran, DEAE-isomalto-oligosaccharides respectively. In one aspect, said isomalto-oligosaccharide ether is DEAE-isomalt 23/75 oligosaccharide. In one aspect, said ether dextrin, dextran ether and isomalto-oligosaccharide ether is respectively carboxialquila -dextrins C 1-10, C 1-10 carboxiaquila dextran, C 1-10 carboxialquila isomalto-oligosaccharide. In one aspect, said isomaltooligosaccharide ether is C 1-10 -isomalto-oligosaccharide carboxyalkyl. [0071] In one aspect, a dextrin, dextran and isomalto-oligosaccharide derivative are selected from the group consisting of hydrogenated isomalto-oligosaccharide, hydrogenated dextran and hydrogenated dextrin. In one aspect, an isomaltooligosaccharide derivative is hydrogenated isomaltooligosaccharide. [0072] In another aspect, a dextrin, dextran and isomalto-oligosaccharide derivative are selected from the group consisting of oxidized isomalto-oligosaccharide, oxidized dextran and oxidized dextrin. In one aspect, an isomalto-oligosaccharide derivative is oxidized isomalto-oligosaccharide. In another aspect, a dextrin, dextran and isomalto-oligosaccharide derivative are selected from the group consisting of hydrogenated / oxidized isomalto-oligosaccharide, hydrogenated / oxidized dextran and hydrogenated / oxidized dextrin. In one aspect, an isomalto-oligosaccharide derivative is hydrogenated / oxidized isomalto-oligosaccharide. [0073] In another aspect, a dextrin, dextran and isomalto-oligosaccharide derivative are selected from the group consisting of DEAE-dextrin, DEAE-dextran, DEAE-isomaltooligosaccharide, carboxyalkyl C 1-10 -dextrin, carboxyalkyl C 1 -10 dextran, C1-10-isomalto-oligosaccharide carboxyalkyl, dextrin ester, dextran ester and isomalto-oligosaccharide ester. In another aspect, an isomalto-oligosaccharide derivative is selected from the group consisting of DEAE-isomalto-oligosaccharide, C1-10-isomalto-oligosaccharide carboxyalkyl and isomaltooligosaccharide ester. 24/75 [0074] In another aspect, a dextrin, dextran and isomalto-oligosaccharide derivative are selected from the group consisting of hydrogenated dextrin, hydrogenated dextran, hydrogenated isomalto-oligosaccharide derivatives, such as selected from the group DEAE consisting of hydrogenated dextrin, hydrogenated DEAE-dextran, DEAE-hydrogenated isomalto-oligosaccharides, hydrogenated -dextrins carboxialquila C 1-10, C 1-10 carboxialquila hydrogenated dextran, C 1-10 carboxialquila -isomalto-hydrogenated oligosaccharide, dextrin ester hydrogenated, hydrogenated dextran ester and hydrogenated isomalto-oligosaccharide ester. In another aspect, an isomalto-oligosaccharide derivative is selected from the group consisting of hydrogenated isomalto-oligosaccharide derivatives, such as selected from the group consisting of hydrogenated DEAE-isomalto-oligosaccharides, C 1-10 isomalto carboxyalkyl -hydrogenated oligosaccharide and hydrogenated isomaltooligosaccharide ester. In another aspect, a dextrin, dextran and isomalto-oligosaccharide derivative are selected from the group consisting of oxidized dextrin, oxidized dextran and oxidized isomalto-oligosaccharide derivatives, such as selected from the group consisting of DEAE-dextrin oxidized, oxidized DEAEdextran, oxidized DEAE-isomalto-oligosaccharides, oxidized C 1-10 -dextrin, oxidized carboxyalkyl C 1-10 -oxidized dextran, oxidized C1-10-isomalto-oligosaccharide oxidized, oxidized dextrin ester and oxidized dextrin ester oxidized isomaltooligosaccharide ester. In another aspect, an isomalto-oligosaccharide derivative is selected from the group consisting of oxidized isomalto-oligosaccharide derivatives, such as selected from the group consisting of oxidized DEAE-isomaltooligosaccharides, oxidized C1-10-isomaltooligosaccharide carboxyalkylalkyl oxidized isomalto-oligosaccharide ester. 25/75 [0075] In a further aspect, the cryoprotectant is a hydrogenated isomalto-oligosaccharide, an oxidized isomalto-oligosaccharide, DEAE-isomalto-oligosaccharide, a C 1-10 -isomaltooligosaccharide carboxyalkyl, an oxidized oligosaccharide ester, an isomalto-oligosaccharide ether or a C 1-10 -isomaltooligosaccharide carboxyalkyl. [0076] In an additional aspect, the cryoprotectant is isomalto-oligosaccharide carboxymethyl or isomalto-oligosaccharide carboxyethyl. [0077] In one aspect, the cryoprotectant is isomalto-oligosaccharide, such as isomalto-oligosaccharide 1. In another aspect, the cryoprotectant is hydrogenated isomalto-oligosaccharide, such as hydrogenated isomaltooligosaccharide 1. [0078] By varying the derivation, different degrees of substitution can be achieved. Suitably, the degree of substitution is in the range of one to three substituents for each unit of glucose. In the case, for example, of DEAE-dextran, preferably approximately one charge group for three glucose units. [0079] In one aspect, the cryoprotectant comprises a cryoprotectant which is one or more of: dextrin, dextran, isomaltooligosaccharide, and derivatives thereof, and wherein said cryoprotectant comprises at least 1% by weight of one or more more among isomalto-oligosaccharides and derivatives thereof that have a weight average molecular weight (M w ) between 300 and 1,650 Da, as well as having a weight average molecular weight (M w ) between 850 and 1,650 Da, based on the total weight dextrin, dextran, isomaltooligosaccharide, and derivatives thereof in said agent. [0080] In an additional aspect, the cryoprotectant comprises a cryoprotectant which is one or more of: dextrin, dextran, isomalto-oligosaccharide and derivatives thereof, wherein said cryoprotectant has a weight average molecular weight (Mw) between 300 and 26/75 9,500 Da, such as between 300 and 7,500 Da, such as between 500 and 7,500 Da. In one aspect, said cryoprotectant has a weight average molecular weight (M w ) of a maximum of 9,500 Da, such as a maximum of 9,000 Da, as maximum 8,000 Da, maximum 7,000 Da, maximum 6,000 Da, maximum 5,000 Da, maximum 4,000 Da maximum 3,000 Da maximum 2,000 Da maximum maximum 1,900 Da, maximum 1,800 Da, maximum 1,700 or maximum 1,650 Da. [0081] In a further aspect, the cryoprotectant comprises a cryoprotectant which is one or more of: dextrin, dextran, isomalto-oligosaccharide, and derivatives thereof, and wherein said cryoprotectant comprises at least 1% in weight of one or more among isomalto-oligosaccharides and derivatives thereof having a weight average molecular weight (M w ) between 300 and 1,650 Da, such as having a weight average molecular weight (Mw) between 850 and 1,650 Da, based on in the total weight of dextrin, dextran, isomalto-oligosaccharide, and derivatives thereof in said agent, and in which said cryoprotectant has a weight average molecular weight (M w ) between 300 and 9,500 Da, such as between 300 and 7,500 Da, such as between 500 and 7,500 Da. [0082] In one aspect, electrically charged derivatives are characterized by the molecular weight distribution of the uncharged starting materials, such as those derived from the dextrans, dextrins and isomalto-oligosaccharide mentioned above. Thus, in one aspect, said dextrans, dextrins and / or isomalto-oligosaccharide derivatives have a weight average molecular weight (M w ) between 300 and 9,500 Da, such as between 300 and 7,500 Da, such as between 500 and 7,500 In a further aspect, said derivatives are derived from isomalto-oligosaccharide which has a weight average molecular weight (M w ) between 850 and 1,650 Da. 27/75 [0083] In one aspect, the cryoprotectant selected from the group consisting of dextran, dextrin, and derivatives thereof has a weight average molecular weight (M w ) between 300 and 9,500 Da, such as between 300 and 7,500 Da, such as between 500 and 7,500 Da. [0084] In one aspect, the cryoprotectant selected from the group consisting of dextran, dextrin, and derivatives thereof has a weight average molecular weight (M w ) between 1,650 and 7,500 Da. [0085] In one aspect, the cryoprotectant selected from the group consisting of dextran, dextrin, and derivatives thereof has a weight average molecular weight between 1,650 and 7,500 Da, and a polydispersity of> 1 and <5. [0086] In one aspect, the cryoprotectant selected from the group consisting of dextran, dextrin and derivatives thereof has a weight average molecular weight (M w ) between 1,650 and 3,500 Da. [0087] In one aspect, the cryoprotectant selected from the group consisting of dextran, dextrin and derivatives thereof has a weight average molecular weight between 1,650 and 3,500 Da, and a polydispersion of> 1 and <5. [0088] In one aspect, the cryoprotectant selected from the group consisting of isomalto-oligosaccharide, and derivatives thereof, has an average molecular weight between 850 and 1,650 Da. [0089] In one aspect, the cryoprotectant selected from the group consisting of isomalto-oligosaccharides and derivatives thereof has a polydispersion of> 1 and <3. [0090] In an additional aspect, the cryoprotectant selected from the group consisting of isomalto-oligosaccharide, and derivatives thereof has a weight average molecular weight (M w ) between 850 and 1,150 Da. [0091] In an additional aspect, the weight fraction of isomaltooligosaccharides that have less than 3 units of glucose is less 28/75 than 15% by weight. In one aspect, the weight fraction of isomaltooligosaccharides that have more than 9 glucose units is less than 20% by weight, such as less than 15% by weight, such as less than 10% by weight. In an additional aspect, the weight fraction of isomaltooligosaccharides that have less than 3 glucose units is less than 15% by weight and the weight fraction of isomaltooligosaccharides that have more than 9 glucose units is less than 20% by weight , such as less than 15% by weight, such as less than 10% by weight. The weight fraction can, for example, be determined as described in Preparation Example 1 and 2 herein. [0092] In one aspect, the cryoprotectant comprises at least 10%, such as 20%, by weight of one or more among isomaltooligosaccharides and derivatives thereof that has a weight average molecular weight (M w ) between 300 and 1,650 Da , as well as having an average molecular weight (M w ) between 850 and 1,650 Da, based on the total weight of dextrin, dextran, isomalto-oligosaccharide and derivatives thereof in said agent. In a further aspect, the cryoprotectant comprises at least 30%, such as 40%, such as 50%, such as 60%, such as 70%, such as 80%, such as 90%, such as 95% or more in weight of one or more among isomaltooligosaccharides and derivatives thereof that have a weight average molecular weight (M w ) between 300 and 1,650 Da, as well as having a weight average molecular weight (M w ) between 850 and 1,650 Da, with based on the total weight of dextrin, dextran, isomalto-oligosaccharide and derivatives thereof in said agent. Dextran and Derivatives of the Same [0093] Dextran can be formed by several bacterial strains, mainly gram-positive, facultative anaerobic coconut, for example, Leuconostoc and Streptococcus strains, as described, for example, in Advances in polymer science, Volume 205 , Polisaccha 29/75 rides II, editor D.Klemm, Springer Verlag. Dextrans for pharmaceutical use have typically been manufactured by specific bacterial strains defined in the US or European Pharmacopoeias, such as, for example, by Leuconostoc Mesenteroides NCTC 10817 or B512 F. The strain NCTC 10817 and B512F has been publicly available since 1971 from the National Collection Type Cultures (Central Public Health Laboratory), UK. [0094] Dextrans are a family of neutral branched polysaccharides that predominantly consist of an α- (1 ^ 6) D-glucose that has a main chain with varying proportions of bonds and branches, depending on the bacteria used in fermentation . The dextran molecule contains a free terminal aldehyde group that is not shown in Formula I. The α- (1 ^ 6) bonds in dextran can vary from 50 to 97% of the total glycosidic bonds. The remaining glycosidic bonds represent α (1 ^ 2), α- (1 ^ 3) and α- (1 ^ 4) bonds linked as branches. Formula I illustrates part of the glucose main chain linked by α- (1 ^ 6) dextran with branching points in 2-, 3- and 4-positions. With the use of the B512F strain mentioned above, the α- (1-6) binding ratio is typically 95% or above. 30/75 FORMULA I [0095] Extremely high molecular weight values are found for native dextrans. Values ranging from 10 7 to 4 x 10 8 Daltons have been reported. In order to produce dextrans useful for many applications, it is therefore necessary to hydrolyze native dextrans to a lower molecular weight. There are several known and available methods for the element skilled in the art, however, hydrolysis can be carried out at approximately pH 1.5, usually with the use of hydrochloric acid, and at a temperature 31/75 of approximately 95 ° C. Through hydrolysis, low molecular weight and glucose dextrans are produced. The hydrolyzate is typically purified and fractionated using a variety of methods, such as sedimentation with alcohol, filtration and other various chromatographic methods, which include membrane filtration. [0096] Dextrans for pharmaceutical use were typically manufactured by specific bacterial strains defined in US or European Pharmacopoeias, such as, for example, by Leuconostoc Mesenteroides NCTC 10817 or B512 F. Both the B512F and NCTC 10817 strain are, as mentioned above , publicly available from the National Collection Type Cultures (Central Public Health Laboratory), UK. [0097] Among dextrans, particularly, Dextran 40 and Dextran 70 have been used for human pharmaceutical use. Other molecular sizes, such as, for example, Dextran 500 and Dextran 5 and molecular weights between them are used outside the cryopreservation area as vehicles for synthesis, for cell separation, as excipients in vaccines or in several other applications, such as preservation of the human cornea. In addition, Dextran 1 has a special use in humans, since pre-injection of Dextran 1 exhibits hapten inhibition and blocks human dextran antibodies, thus preventing potential allergic reactions known to occur occasionally after administration of dextran from high molecular weight in humans. 1 Dextran, Dextran 40 and Dextran 70 are products well described Pharmacopoeia (European Pharmacopoeia, the seventh edition, volume 2, pages 1816-1819). [0098] Dextran is also an excellent raw material used to synthesize water-soluble polymers. [0099] The following are examples of dextran derivatives: 1) Hydrogenated dextran that can be synthesized by the area 32/75 dextran with a reducing agent, such as borohydride, under alkaline conditions, for example, at pH 8 to 12, reducing the aldehyde end groups in sorbitol. 2) Dextran ethers that can be synthesized by methods known to those skilled in the art. As an example, 2- (Diethylamino) ethyl dextran (DEAE dextran) (shown in Reaction Scheme 1) can be mentioned, which can be synthesized by the reaction of dextran with (2-chloroethyl) diethylammonium chloride in alkaline solution. ^ 2Π5 -C 2 H 4 -N (C 2 H 5 ) 2 Ο 2 Η 4 -Ν (Ο 2 Η 5 ) 2 Reaction scheme 1: DEAE dextran containing groups 2 (diethylamino) ethyl (A) and 2 - [(2- (diethylamino) ethyl] diethylammonium] ethyl (B) [00100] Another example is carboxyalkyl Ci_i 0 dextran, such as carboxymethylxtran ( CMD), as shown in Reaction Scheme 2, which can be synthesized by reaction with monochloric acetic acid (MCA) under strong alkaline conditions. REACTION SCHEME 2 33/75 3) Dextran esters, such as dextran acetate, which can be synthesized by reacting dextran with acetic acid anhydride. R: H; CH 3 CO REACTION SCHEME 3 4) Oxidized dextran can, for example, be synthesized by means of a sodium hypochlorite in a basic aqueous solution. 5) Dextran partially oxidized / hydrogenated. A method of preparing such derivatives is disclosed, for example, in the document under paragraph 2 . US 6,977,249, which is hereby incorporated by reference. As an example, a dextran can be mentioned which is prepared by a process in which the molecular weight of a dextran is reduced by hydrolysis, and the functional aldehyde end groups thereof are converted to alcohol groups by means of hydrogenation; characterized by the fact that the hydrogenation is only partial, leaving a maximum of 15% by weight of reduction sugar, calculated based on the total amount of carbohydrates, and said dextran is subsequently subjected to oxidation, and said hydrogenation and oxidation is carried out to obtain dextran with substantially all aldehyde groups converted to alcohol and carboxylic groups, and said dextran product with no functional aldehyde group or functional carboxylic acid group 34/75 onal in the intermediate glycosyl groups; wherein the hydrogenation is carried out by means of sodium borohydride in aqueous solution; and in which the oxidation is carried out by means of sodium hypochlorite in a basic aqueous solution. 6) In addition, substituted DEAE, substituted C 1-10 carboxyalkyl, hydrogenated and / or oxidized dextran esters and ethers above can be prepared by methods known to the skilled artisan similar to those described above. Isomalto-Oligosaccharides and Derivatives of the Same [00101] Isomalto-oligosaccharides are glucose oligomers with a main chain linked to aD- (1,6). In one aspect, the isomalto-oligosaccharide described in this document is based on dextran and is produced by low molecular weight dextran hydrolysis. In an additional aspect, the isomalto-oligosaccharide described has a weight average molecular weight (M w ) between 300 and 1,650 Da, just as it has a weight average molecular weight (M w ) between 850 and 1,650 Da. In one aspect, the isomalto-oligosaccharide described in this document is hydrolyzed dextran which has a weight average molecular weight (Mw) between 850 and 1,650 Da. [00102] Starting from isomalto-oligosaccharide, derivatives of it characterized by the change of the aldehyde terminal groups of reduction in glycitol / sorbitol can be prepared. Conversion from isomalto-oligosaccharide to hydrogenated isomalto-oligosaccharide can be carried out by treating the isomalto-oligosaccharide with a reducing agent, such as, for example, borohydride, under alkaline conditions, as shown in Reaction Scheme 4 below: 35/75 REACTION SCHEME 4 [00103] With the processes described above to produce dextran derivatives, isomalto-oligosaccharide derivatives can also be produced, for example, by reaction with ethyl (2chloroethyl) diethylammonium chloride producing 2- (diethylaminodextran) ethyl (DEAE ) isomalto-oligosaccharide. Another option is to produce isomalto-oligosaccharide derivatives by reacting with monochloroacetic acid (MCA) to synthesize isomalto-oligosaccharide carboxymethyl. It will be obvious to the person skilled in the art the production of additional derivatives of hydrogenated isomalto-oligosaccharide by reaction with, respectively, (2-chloroethyl) diethylammonium chloride and monochloroacetic acid, as described above under dextran and isomaltooligosaccharide. 36/75 Oligo-Isomaltose [00104] With dextrans as starting materials and Dextran 1 (isomalto-oligosaccharide) as an intermediate, it is possible to synthesize oligo-isomaltose, characterized by a total lack of α- (1 ^ 2), α- branching side chains (1 ^ 3) and α- (1 ^ 4) that define the dextran molecules. In the present context, oligoisomaltose is considered as a subset of isomalto-oligosaccharides. Thus, in one aspect, oligoisomaltose has a weight average molecular weight (Mw) between 300 and 1,650 Da, such as between 850 and 1,650 Da, preferably between 850 and 1,150 Da, and which has a total lack of side chains branching α- (1 ^ 2), α- (1 ^ 3) and α- (1 ^ 4). Obviously, the same synthesis of derivatives described above for isomalto-oligosaccharide can be performed with the use of oligo-isomaltose. Dextrin and Derivatives of the Same [00105] Dextrins are a group of low molecular weight carbohydrates produced by the hydrolysis of starch. Dextrins are like polymers of dextrans that consist of a mixture of molecules with varying lengths of the main glucose chain. Before using dextrins, they are typically purified and fractionated, for example, by applying hydrolysis or one or more processes of sedimentation of alcohol and / or by means of several chromatographic methods, which include the membrane processing that applies one or more membranes with specific cut-off values in order to obtain the desired molecular weight and weight distribution. [00106] Dextrins are mixtures of polymers of glucose units linked by α- (1 ^ 4) or α- (1 ^ 6) glycosidic bonds, as shown in Formula II. 37/75 OH HO FORMULA II [00107] Dextrin derivatives can be produced by methods known to the person skilled in the art, similar to those described above under dextran and isomalto-oligosaccharide. Cryopreservation [00108] In order to avoid contamination of the sample to be cryopreserved, it is preferable that the cryoprotectant is sterile, and that other optional components of the cryopreservation agent / composition are also sterile. [00109] In some applications, it could be useful to supplement a cryoprotectant selected from the group consisting of dextrin, dextran, isomalto-oligosaccharide, and derivatives thereof, with an additional cryoprotectant, in order to reduce the concentration of such additional cryoprotectant, preferably at non-toxic concentrations. This can be particularly useful for specific cell types, such as hepatocytes or pluripotent stem cells. In a further aspect, the cryoprotective agent thus further comprises 38/75 at least one additional cryoprotectant selected from the group consisting of acetamide, agarose, alginate, 1-analine, albumin, ammonium acetate, butanediol, chondroitin sulfate, chloroform, choline, diethylene glycol, dimethyl acetamide, dimethyl formamide , dimethyl sulfoxide (DMSO), erythritol, ethanol, ethylene glycol, formamide, glucose, glycerol, aglycerophosphate, glycerol monoacetate, glycine, hydroxyethyl starch, inositol, lactose, magnesium chloride, magnesium sulphate, maltose, mannitol, mannose, methanol, methyl acetamide, methylformamide, methyl ureas, phenol, pluronic polyols, polyethylene glycol, polyvinylpyrrolidone, proline, propylene glycol, pyridine N-oxide, ribose, serine, sodium bromide, sodium chloride, sodium iodide, sodium nitrate, sodium sulfate, sorbitol, sucrose, trehalose, triethylene glycol, trimethylamine acetate, urea, valine and xylose. In one aspect, said additional cryoprotectant is DMSO. An advantage of adding DMSO in a reduced amount may be the fact that, for very fragile cells, additional protection can be obtained. In a preferred aspect, the cryoprotective agent is free or substantially free of DMSO. Thus, in yet another preferred aspect, said dextrin, dextran, isomaltooligosaccharide, or a derivative thereof, is the only cryoprotectant in the cryoprotective agent. A cryoprotectant free or substantially free of DMSO may not require washing after thawing the sample. The thawed sample can then be directly suspended in a culture medium to immediately start a culture process, without having to wash the sample, or can be used directly on a patient without a washing step that potentially leads to substantial cell loss. . Another advantage of using a cryoprotectant free or substantially DMSO free is that the sample can be exposed to the cryoprotectant for a longer period, without damage, allowing for a more efficient working process. 39/75 [00110] In another aspect, the cryoprotectant additionally comprises at least one antifreeze protein and / or anti-freeze glycoprotein, such as in an amount from 0.01 to 1 mg / ml of the cryoprotectant . An example of an antifreeze glycoprotein is Type I AFP from scorpionfish, which is a unique long amphipathic alpha helix. [00111] The cryoprotective agent or composition may comprise additional substances to improve the viability of the sample. Examples of such substances include IAPs (apoptosis inhibitors), inhibitors of rho-associated protein kinase signaling routes (ROCK), growth factors such as EGF, FGF, PDGF, IGF, EPO, BDNF, TGF , TNF, VEGF. In a further aspect, any components of human, bovine, equine and canine serum can be mentioned. The cryoprotective agent or composition can also comprise a growth medium. In one aspect, a growth medium comprising p-catenin / P300 antagonist and an Activin / TGFp linker, such as, for example, ID-8 in conjunction with Activin and TGFp, can be used. This type of environment is particularly useful for culturing pluripotent stem cells, particularly embryonic stem cells as, for example, described in the document under n. WO 2013/054112. Another example is the standard knock-out medium that comprises replacement of KnockOut, DMEM / F12 serum with GlutaMAX ™, FGF, NEAA and BME supplement. Another example is the mTSER TM system. Other examples of growth media that depend on the sample to be cryopreserved are well known to the skilled person. [00112] The cryoprotective agent, as disclosed herein, can be in the form of a powder, such as a spray-dried or lyophilized powder. [00113] In an additional aspect, said cryoprotection agent is 40/75 in the form of a solution. The agent can therefore further comprise a solvent, such as, for example, sterile water. In one aspect, said agent comprises from 30% to 70% by weight of said cryoprotectant, such as from 40% to 65% by weight or from 50% to 60% by weight of said cryoprotectant. [00114] The sample, such as cells, tissue or organs, to be cryopreserved can also be in contact with a pH buffer compatible with freezing which more typically comprises at least a basic saline solution, an energy source (for example , glucose) and a buffer capable of maintaining a neutral pH at low temperatures. Well-known materials include, for example, Dulbecco-modified Eagle medium (DMEM). This material can also be included as part of the cryopreservation and / or agent composition. [00115] One aspect disclosed in the present document is a cryopreservation composition comprising a cryoprotection agent, as described in the present document, such a cryopreservation composition further comprises a sample to be cryopreserved. [00116] An additional aspect disclosed in this document is a cryopreserved composition that comprises a cryoprotection agent and a sample that has been cryopreserved or is in the process of being cryopreserved, as described in the present document, the term, a cryopreserved composition refers to a cryopreservation composition, which is in the process of being cryopreserved or has already been cryopreserved. [00117] An additional aspect disclosed in this document is a cryopreserved composition that comprises a substrate or growth medium for the sample to be cryopreserved. [00118] In one aspect, the sample is selected from the group consisting of organs, cells and tissues, such as mammals. In 41/75 an additional aspect, the sample is organs, cells, blood or tissues. Examples of such cells to be cryopreserved are cells cultured in vitro that include primary cells, cell lines, cells classified in vitro that include human blood cells, and fertilized eggs of animal and human origin. Additional examples are sperm cells, embryonic stem cells, IPS cells, mesenchymal stem cells, hematopoietic stem cells, neuronal stem cells, umbilical cord blood stem cells, hepatocytes, nerve cells, cardiomyocytes, vascular endothelial cells, vascular smooth muscle cells and blood cells. In an additional aspect, the sample is cells selected from the group consisting of mesenchymal stem cells, hematopoietic stem cells, embryonic stem cells, IPS cells, keratinocytes, preferably hematopoietic stem cells, such as stem cells positive CD34 blood, mesenchymal stem cells, embryonic stem cells and IPS cells. In an additional aspect, the sample is selected from the group consisting of mesenchymal stem cells and hematopoietic stem cells. In one aspect, the cell is of animal or human origin. Examples of organs are lung, liver, kidney, heart, ovaries and pancreas. Examples of tissues are bone marrow, skin, ovaries, testicles, blood vessels, connective tissue, preferably ovarian and connective tissue. In an additional aspect, blood is selected from the group consisting of umbilical cord blood, and mobilized peripheral blood, preferably umbilical cord blood. In a further aspect, the sample is a cell-containing body fluid, such as blood, menstrual fluid or amniotic fluid. [00119] Depending on the specific sample to be cryoprotected, the cryoprotectant is typically present in the composition to be cryopreserved in an amount from 1 to 50% by weight, such as par 42/75 from 2 to 50% by weight, such as from 4 to 45% by weight, or from 6 to 20% by weight, from 6 to 12% by weight, preferably from from 6 to 10% by weight, more preferably from 7 to 9% by weight. In one aspect, the cryoprotectant is present in the composition to be cryopreserved in an amount of a maximum of 60% by weight, such as in an amount of a maximum of 55% by weight, such as in an amount of a maximum of 50% by weight, such as in an amount of a maximum of 45% by weight, such as in an amount of a maximum of 40% by weight, such as in an amount of a maximum of 35% by weight. In another aspect, the cryoprotectant is typically present in an amount of at least 2% by weight, such as present in an amount of at least 4% by weight, as present in an amount of at least 6% by weight, such as as present in an amount of at least 6% by weight, as present in an amount of at least 7% by weight. [00120] If the composition to be cryoprotected comprises an additional cryoprotectant, such as DMSO, the additional cryoprotectant is typically present in an amount less than 8% by weight, such as from 1 to 8% by weight, such as For example, in an amount below 5% by weight, such as below 4% by weight, such as from 1 to 4% by weight. [00121] In conventional cryopreservation techniques, a sample is collected, suspended in a storage solution and then preserved by freezing. When the sample, like cells, is to be used, they are thawed, for example, cells taken from human donor sources are brought back to normal human body temperature (ie approximately 37 ° C) and, then placed in a cell culture medium. [00122] In the present method of cryopreservation, the sample is protected during cryopreservation by being placed in contact with a 43/75 cryoprotection agent, as described in this document, before freezing at cryopreservation temperature. Putting in contact with the cryoprotectant means that the sample is made to be in contact, in some way, with the cryoprotectant, so that, during the temperature reduction until the cryopreservation temperature, the sample is protected by the cryoprotectant in the cryopreservation composition. For example, cells can be brought into contact with the cryoprotection agent by filling suitable wells on a plate to which the cells to be protected are fixed, suspending the cells in a solution of the cryoprotection agent or adding the cryoprotection agent, for example, in freeze-dried form to cells, blood or organ already in a solution of, for example, buffer, or resuspending the cell pellet after centrifugation in the cryoprotection agent by placing the cells in a solution etc. [00123] In one aspect, this method discloses a method for cryopreserving a sample, which comprises the steps of placing a sample to be cryopreserved in contact with a cryoprotection agent, as defined in this document, to obtain a composition of cryopreservation and subsequently reduce the temperature of the cryopreservation composition to a cryopreservation temperature. [00124] In a further aspect, a method for cryopreserving a composition, as defined in this document, by reducing the temperature of said composition to a cryopreservation temperature is disclosed in the present document. [00125] The rate of change from room temperature to 1 to 2 ° C below the freezing point of the solution can have a greater effect on the final viability, if the cells are sensitive to thermal shock. 44/75 [00126] Between 3.5 ° C and -5 ° C, the sample is usually induced to freeze by introducing an ice crystal, touching the surface of the medium with a cold probe, by mechanical vibration or by reducing temperature up quickly until ice nucleation occurs. Since freezing is an exothermic process, heat must be conducted away from the freezing solution. This can be done by keeping the samples immersed in a liquid with a low freezing point or by providing a substantial heat sink. As ice forms in the extracellular medium, more and more free water becomes bound in the ice phase. The cell membranes, being hydrophobic, act as a barrier to the nucleation of intracellular ice and, therefore, unfrozen cells are exposed to a progressively hypertonic solution. The concentration of extracellular salt increases as a result of the sequestration of water in the ice. Non-frozen cells contract due to the transport of water out of the cell in response to the osmotic imbalance between the intracellular and extracellular fluid phases. The sample is then cooled at a finite rate, which needs to be optimized for each cell type. [00127] The ideal cooling rate is determined by the permeability of the cell membrane to water, the ratio of cell surface to volume, along with the type and concentration of cryoprotective additives in the cryoprotective agent, as described in this document. For most nucleated mammalian cells frozen in glycerol or DMSO, the ideal cooling rate is usually between about 0.3 to 10 ° C per minute. Continuous cooling between about 4 ° C and -80 ° C is the most commonly used. Once the sample reaches approximately -80 ° C, it can be transferred directly to liquid nitrogen (-196 ° C) or to the liquid nitrogen vapor phase for storage. Another method used for 45/75 cryopreservation is the vitrification technology, in which it is possible to obtain very fast cooling rates from 1,000 ° C to 2,000 ° C / min. With this technology, a specialized vitrification device, containing the cryopreservation composition with the sample, is directly placed in liquid nitrogen. In one aspect, the cryopreservation temperature is reached at a rate of 0.05 to 15, such as 0.1 to 10, such as 0.2 to 8, such as 0.3 to 6, such as 0.4 to 4, such as 0.5 to 2 ° C per minute. In another aspect, the cryopreservation temperature is reached at a rate of 500 to 3,000, such as 800 to 2,500, such as 1,000 to 2,000, such as 1,200 to 1,800 ° C per minute. [00128] The duration of storage of viable cell at liquid nitrogen temperature is dependent, predominantly, on the rate of generation of free radicals caused by the background of cosmic rays. [00129] For example, the half-life for mammalian embryos stored in liquid nitrogen has been estimated to be approximately 30,000 years. It is important not to allow frozen cells to heat up above their storage temperature for even brief periods of time. Intermittent heating promotes rapid migratory recrystallization, which can damage cell structure and decrease overall viability. [00130] In an additional aspect, the sample is thawed after cryopreservation. The ideal rate of defrosting of the sample is dependent on the freezing conditions used and the specific sample to be preserved. In general, for single frozen cells in suspension, and for tissues such as heart valves, a rapid rate of heating is desirable. Such rapid heating limits the growth of ice crystals in frozen samples and is often an absolute requirement for high survival. With many tissues, this heating can be accomplished by shaking the sample in a water bath at 37 to 42 ° C. The rationale for warming 46/75 is that it limits the growth of ice crystals that were formed during cooling. [00131] Some fabrics may be sensitive to rapid heating. This is due to the transient osmotic shock, due to the fact that the cells are exposed to an extracellular hypertonic solution as the ice melts and are forced to rehydrate in order to maintain their osmotic balance. For other, more sensitive samples, metabolic processes can be reactivated or brought back to normal levels by successive dilutions with the use of serum or other high molecular weight polymers in the thawing medium. [00132] Upon completion of the thawing procedure, the cells are still exposed to multimolar concentrations of cryoprotective agents, which need to be gradually diluted to return the cells to an isotonic medium. For mammalian cells, a stepwise dilution protocol is typically used. Sample dilution is usually performed, preferably at 37 ° C, in order to reduce the effects of both osmotic shock and cryoprotectant toxicity. In a further aspect, the concentration of said cryoprotectant is from 4 to 45% by weight, such as from 4 to 20% by weight, as well as from 5 to 15% by weight, from 6 to 12% by weight, preferably from 6 to 10% by weight, or more preferably, from 7 to 9% by weight of cryoprotectant. [00133] In an additional aspect, the sample temperature in the cryopreservation composition is reduced to a cryopreservation temperature below -50 ° C, such as between -50 ° C to - 196 ° C, such as between -80 ° C a - 196 ° C. [00134] In one aspect, the cryoprotection agent is used in a bank method. In one aspect, the cryoprotection agent is used in a clinical bank method. In one aspect, the cryoprotective agent is used in a mobilized peripheral blood bank method. 47/75 [00135] In one aspect, the cryoprotection agent is used in a clinical bank method, such as in stem cell transplantation for malignant diseases or in an organ transplant. In one aspect, the cryoprotection agent is used in a mobilized peripheral blood bank method, bone marrow bank method or in an umbilical cord bank method. [00136] In one aspect, the cryoprotection agent is used in a cord bank method or in an umbilical cord bank method. In one aspect, the cryoprotective agent is used in an adipose tissue bank method or in a dental pulp tissue bank method. In an additional aspect, the cryoprotection agent is used in a bank breeding method. The following are the Additional Modalities: 1. A cryoprotective agent comprising a cryoprotectant which is one or more of: dextrin, dextran, isomaltooligosaccharide, and derivatives thereof, such as being one or more of: dextran, isomalto-oligosaccharide, and derivatives thereof, and a) wherein said cryoprotection agent comprises at least 1% by weight of one or more of isomalto-oligosaccharide and derivatives thereof based on the total weight of dextrin, dextran, isomalto-oligosaccharide and derivatives thereof in said agent, and /or b) in which said cryoprotectant has an average molecular weight (M w ) between 300 and 9,500 Da. 2. A cryoprotective agent comprising one or more cryoprotectants selected from the group consisting of dextrin, dextran, isomalto-oligosaccharide and derivatives thereof, as selected from the group consisting of dextran, isomaltooligosaccharide, and derivatives thereof , and a) in which said cryoprotection agent comprises at least 48/75 minus 1% by weight of one or more among isomalto-oligosaccharides and derivatives thereof which has a weight average molecular weight (M w ) between 300 and 1,650 Da, based on the total weight of dextrin, dextran, isomalto-oligosaccharide and derivatives thereof in said cryoprotection agent, or b) in which said cryoprotectant has an average molecular weight (M w ) between 300 and 9,500 Da, or c) in which said cryoprotection agent comprises at least 1% by weight of one or more among isomalto-oligosaccharides and derivatives thereof having a weight average molecular weight (M w ) between 300 and 1,650 Da, based on the total weight of dextrin, dextran, isomalto-oligosaccharide and derivatives thereof in said cryoprotectant, and said cryoprotectant has a weight average molecular weight (M w ) between 300 and 9,500 Da. 3. The agent, according to any of the modalities 1 to 2, in which said cryoprotectant has a weight average molecular weight (M w ) between 300 and 7,500 Da. 4. The agent, according to any one of the modalities 1 to 3, in which said cryoprotectant is one or more selected from the group consisting of isomalto-oligosaccharide, and derivatives thereof that has an average molecular weight (M w ) between 300 and 1,650. 5. The agent, according to any of the modalities 1 to 4, wherein said cryoprotection agent comprises at least 1% by weight of one or more among isomalto-oligosaccharides and derivatives thereof, which has an average molecular weight ( Mw) between 300 and 1,650 Da, based on the total weight of dextrin, dextran, isomalto-oligosaccharide and derivatives thereof in said cryoprotection agent. 6. The agent, according to any of the modalities 49/75 to 5, wherein said isomalto-oligosaccharide, and derivatives, has a weight average molecular weight (M w ) between 850 and 1,650 Da. 7. The agent, according to any of modalities 1 to 6, for cryopreserving a sample, and in which said sample is selected from the group consisting of organs, cells and tissue, as selected from the group that consists of mammalian organs, mammalian cells and mammalian tissues. 8. The agent, according to any of modalities 1 to 7, for cryopreserving a sample, and in which said sample is for transplantation. 9. The agent, according to any of modalities 1 to 8, for cryopreserving a sample, and in which said sample is functional after cryopreservation. 10. The agent, according to any of modalities 1 to 9, in which said sample is an organ, such an organ is functional as measured by the physiological function of said organ after cryopreservation, and / or in which said sample is tissue, such tissue is functional as measured by the ability of such tissue to integrate with the surrounding tissue and / or in which said sample is cells, such cells are functional as measured by the viability of said cells after cryopreservation. 11. The agent, according to any of the modalities 1 to 10, in which said cryoprotectant has a weight average molecular weight (M w ) between 1,650 and 7,500 Da. 12. The agent, according to any of the modalities 1 to 11, in which said cryoprotectant has a weight average molecular weight (M w ) between 500 and 3,500 Da. 13. The agent, according to any of the modalities 1 to 12, in which said cryoprotectant has a weight average molecular weight (M w ) between 1,650 and 3,500 Da. 50/75 14. The agent, according to any of modalities 1 to 13, in which said cryoprotectant has a polydispersion Pd, in which Pd is> 1 and <5. 15. The agent, according to any of modalities 1 to 14, in which said cryoprotectant has a weight average molecular weight (M w ) between 850 and 1,650 Da. 16. The agent, according to any of the modalities 1 to 15, in which said cryoprotectant has a weight average molecular weight (M w ) between 850 and 1,150 Da. 17. The agent, according to any of the modalities 1 to 16, in which said cryoprotectant has a polydispersion Pd, in which Pd is> 1 and <3. 18. The agent, according to any of modalities 1 to 17, which comprises at least 10% by weight of one or more among isomalto-oligosaccharide and derivatives thereof based on the total weight of dextrin, dextran, isomalto-oligosaccharide and derived therefrom in said agent. 19. The agent, according to any of modalities 1 to 18, wherein the weight fraction of isomalto-oligosaccharides that have less than 3 glucose units is less than 15% by weight. 20. The agent, according to any of modalities 1 to 19, wherein the weight fraction of isomalto-oligosaccharides that have more than 9 glucose units is less than 20% by weight. 21. The agent, according to any of modalities 1 to 20, in which the weight fraction of isomalto-oligosaccharides that have less than 3 glucose units is less than 15% and the weight fraction of isomalto-oligosaccharides that have more than 9 glucose units is less than 20% by weight, such as less than 15% by weight, such as less than 10% by weight. 22. The agent, according to any of the modalities 51/75 from 1 to 21 comprising at least 30% by weight, at least 40% by weight, at least 50% by weight, at least 60% by weight, at least 70% by weight, at least 80% by weight , at least 90% by weight, at least 95% by weight or more than one or more among isomalto-oligosaccharide and derivatives thereof based on the total weight of dextrin, dextran, isomalto-oligosaccharide and derivatives thereof in said agent. 23. The agent, according to any one of modalities 1 to 22, wherein said cryoprotectant is isomalto-oligosaccharide, such as isomalto-oligosaccharide which has a weight average molecular weight (M w ) between 850 and 1,150 Da. 24. The agent, according to any one of modalities 1 to 23, wherein said isomalto-oligosaccharide and derivatives thereof are based on dextran. 25. The agent, according to any one of modalities 1 to 24, wherein said derivative is a dextrin, dextran and isomalto-oligosaccharide derivative selected from the group consisting of hydrogenated isomalto-oligosaccharide, hydrogenated dextran, hydrogenated dextrin , oxidized isomalto-oligosaccharide, oxidized dextran, oxidized dextrin, dextrin ester, dextran ester, isomalto-oligosaccharide ester, dextrin ether, dextran ether, partially hydrated / partially dextrin / dextrin / dextrin oxidized and partially hydrogenated / oxidized isomaltooligosaccharide and derivatives thereof, as selected from the group consisting of hydrogenated isomalto-oligosaccharide, hydrogenated dextran, hydrogenated dextrin, oxidized isomalto-oligosaccharide, oxidized dextran, oxidized dextrin, DEA dextran, DEAE-isomaltooligosaccharides, carboxyalkyl C 1-10 -dextrin, carboxyalkyl C 1-10 dextran, carboxy C1-10-isomalto-oligosaccharide alkyl, dexyl ester 52/75 trine, dextran ester and isomalto-oligosaccharide ester and derivatives thereof. 26. The agent according to any one of embodiments 1 to 25, wherein said derivative is a hydrogenated isomalto-oligosaccharide, an oxidized isomalto-oligosaccharide, DEAE-isomaltooligosaccharide, a C 1-10 oxidized isomalto-oligosaccharide or an carboxyalkyl C 1-10 isomalto-oligosaccharide. 27. The agent, according to any one of embodiments 1 to 26, wherein said derivative is hydrogenated isomalto-oligosaccharide, such as hydrogenated isomalto-oligosaccharide which has a weight average molecular weight (M w ) between 850 and 1,150 Da. 28. The agent according to any one of embodiments 25 to 27, wherein said C 1-10 isomaltooligosaccharide carboxyalkyl is isomalto-oligosaccharide or carboxyethyl isomalto-oligosaccharide. 29. The agent, according to any of modalities 1 to 28, which comprises at least one additional cryoprotectant selected from the group consisting of acetamide, agarose, alginate, 1-analin, albumin, ammonium acetate, butanediol, sulfate chondroitin, chloroform, choline, diethylene glycol, dimethyl acetamide, dimethyl formamide, dimethyl sulfoxide (DMSO), erythritol, ethanol, ethylene glycol, formamide, glucose, glycerol, a-glycerophosphate, glycerol monoacetate, glycine, hydroxyethyl starch, in , lactose, magnesium chloride, magnesium sulfate, maltose, mannitol, mannose, methanol, methyl acetamide, methylformamide, methyl ureas, phenol, pluronic polyols, polyethylene glycol, polyvinylpyrrolidone, proline, propylene glycol, pyridine N-oxide, ribose, serine, sodium bromide, sodium chloride, sodium iodide, sodium nitrate, sodium sulfate, sorbitol, sucrose, trehalose, triethylene glycol, trimethylamine acetate, urea, valine and xylose. 30. The agent, according to any of the modalities 53/75 from 1 to 29, wherein said additional cryoprotectant is DMSO. 31. The agent, according to any of modalities 1 to 30, which is substantially free of DMSO. 32. The agent, according to modality 31, which is free of DMSO. 33. The agent, according to any of modalities 1 to 32, which comprises a cryoprotectant, as defined in modality 1, as the only cryoprotectant. 34. The agent, according to any of modalities 1 to 33, wherein said agent is in the form of a powder. 35. The agent, according to any one of embodiments 1 to 34, wherein said agent is in the form of a spray-dried or lyophilized powder. 36. The agent, according to any of modalities 1 to 35, wherein said agent is in the form of a solution. 37. The agent, according to any of embodiments 1 to 36, wherein said agent comprises from 30% to 70% by weight of said cryoprotectant, such as from 40% to 65% by weight or at from 50% to 60% by weight of said cryoprotectant. 38. The agent, according to any of embodiments 1 to 37, wherein said agent comprises from 30% to 70% by weight of said additional cryoprotectant, such as from 40% to 65% by weight or from 50% to 60% by weight of said additional cryoprotectant. 39. The agent, according to any one of modalities 1 to 38, which additionally comprises a substrate or growth medium for a sample to be cryopreserved. 40. The agent, according to any one of modalities 1 to 39, which further comprises any protein that belongs to IAPs (inhibitors of apoptosis), inhibitors of the pathways of 54/75 rho-associated protein kinase (ROCK) signaling and / or any growth factor, such as EGF, FGF, PDGF, IGF, EPO, BDNF, TGF, TNF and / or VEGF. 41. The agent, according to any of modalities 1 to 40, which further comprises any component of human, bovine, equine or canine serum. 42. The agent, according to any of modalities 1 to 41, in which said cryoprotectant is sterile. 43. A cryopreservation composition that comprises a cryoprotection agent as defined in any one of embodiments 1 to 42, such a cryopreservation composition further comprises a sample to be cryopreserved. 44. The cryopreservation composition, according to modality 43, in which the sample is selected from the group consisting of organs, cells, such as isolated cells or body fluids containing cells, for example, blood and tissues. 45. The cryopreservation composition according to modality 44, in which the sample is selected from the group consisting of mammalian organs, mammalian cells and mammalian tissues, such as a sample selected from the group consisting of in mammalian organs, mammalian cells and mammalian tissues for transplantation. 46. The cryopreservation composition, according to any of modalities 43 to 45, wherein said sample is cells selected from the group consisting of somatic cells, which include all types of tissue-derived cells, such as cells - mesenchymal stem, tissue-specific progenitor cells, keratinocytes, fibroblasts, chondrocytes, bone cells, or cardiomyocytes, blood-derived cells, such as hematopoietic stem cells, macrophages, platelets, erythrocytes, or stem cells, which 55/75 include all types of pluripotent cells, totipotent cells and unipotent cells, and germ layer cells. 47. The cryopreservation composition, according to any of the modalities 43 to 46, in which said sample are cells selected from the group consisting of keratinocytes, fibroblasts, mesenchymal stem cells, macrophages and hematopoietic stem cells, such as like CD34 positive blood stem cells. 48. The cryopreservation composition, according to any of the modalities 43 to 45, wherein said sample is tissue selected from the group consisting of ovarian tissue, testicular tissue, umbilical cord tissue, placental tissue, connective tissue , cardiac tissue, tissue from muscle, bone, and cartilage tissue, endocrine tissue and neural tissue. 49. The cryopreservation composition, according to any of the modalities 43 to 45, wherein said sample is a body fluid containing a cell selected from the group consisting of blood, such as umbilical cord blood, peripheral blood, and mobilized peripheral blood, amniotic fluid, semen, cerebrospinal fluid, menstrual fluid blood, and bone marrow aspirates. 50. The cryopreservation composition, according to any of the modalities 43 to 45, in which said sample is an organ selected from the group consisting of lung, heart, kidney, liver, umbilical cord and ovaries. 51. The cryopreservation composition, according to any one of the modalities 43 to 45, comprising said cryoprotectant in an amount from 1 to 50% by weight such as from 2 to 50% by weight, from 4 to 45% by weight, from 6 to 12% by weight, preferably from 6 to 10% by weight, or more preferably, from 7 to 9% by weight. 52. The cryopreservation composition, according to which 56/75 or one of embodiments 43 to 51, wherein said composition comprises DMSO in an amount less than 8% by weight, such as from 1 to 8%. 53. The cryopreservation composition, according to any of modalities 43 to 52, in which said sample is functional after cryopreservation. 54. The cryopreservation composition, according to any of modalities 43 to 53, wherein said composition comprises DMSO in an amount less than 8% by weight, less than 4% by weight, such as from 1 to 4 %. 55. A method for cryopreserving a sample, which comprises placing a sample to be cryopreserved in contact with a cryoprotection agent, as defined in any of modalities 1 to 42, to obtain a cryopreservation composition and subsequently reduce the temperature of the cryopreservation composition. cryopreservation at a cryopreservation temperature. 56. The method, according to modality 55, in which the composition of cryopreservation is as defined in any of the modalities 43 to 54. 57. A method for cryopreserving a composition, as defined in any of embodiments 43 to 56, by reducing the temperature of said composition to a cryopreservation temperature. 58. The method, according to any of the modalities 55 to 57, in which the cryopreservation temperature is reached at a rate of 0.05 to 15, such as 0.1 to 10, such as 0.2 to 8, such as 0.3 to 6, such as 0.4 to 4, such as 0.5 to 2 ° C per minute. 59. The method, according to any of the modalities 55 to 58, in which the concentration of said cryoprotectant is from 4 to 20% by weight, as well as from 5 to 15% by weight, from 6 The 57/75 12% by weight, preferably from 6 to 10% by weight, or more preferably, from 7 to 9% by weight. 60. The method, according to any of the modalities 55 to 59, in which the temperature of the sample in the cryopreservation composition is reduced to a temperature below - 50 ° C, such as between - 50 ° C to - 196 ° C , such as -80 ° C to -196 ° C. 61. The method, according to any of modalities 55 to 60, in which the sample is thawed after cryopreservation. 62. The method, according to any of modalities 55 to 61, in which said sample is functional after cryopreservation. 63. The method, according to any of the modalities 55 to 62, in which the sample to be cryopreserved is selected from the group consisting of organs, cells and tissues. 64. The method, according to any of the modalities 55 to 63, which is a clinical bank method. 65. The method, according to any one of the modalities 55 to 64, which is a bank method, such as a mobilized peripheral blood bank method, marrow bank method, an adipose tissue bank method, a dental pulp tissue bank method, a breeding bank method or an umbilical cord bank method. 66. Use of a cryoprotective agent comprising one or more cryoprotectants selected from the group consisting of dextrin, dextran, isomalto-oligosaccharide, and derivatives thereof, as selected from the group consisting of dextran, isomalto-oligosaccharide , and derivatives thereof; and a) wherein said cryoprotection agent comprises at least 1% by weight of one or more among isomalto-oligosaccharides and derivatives thereof 58/75 has a weight average molecular weight (M w ) between 300 and 1,650 Da, based on the total weight of dextrin, dextran, isomaltooligosaccharide and derivatives thereof in said cryoprotection agent, or b) in which said cryoprotectant has a weight average molecular weight (M w ) between 300 and 9,500 Da, or c) wherein said cryoprotection agent comprises at least 1% by weight of one or more of isomalto-oligosaccharides and derivatives thereof having a weight average molecular weight (M w ) between 300 and 1,650 Da, based on the total weight of dextrin, dextran, isomalto-oligosaccharide and derivatives thereof in said cryoprotection agent, and said cryoprotectant has a weight average molecular weight (M w ) between 300 and 9,500 Da, to cryopreserve a sample, and in which said sample is selected from the group consisting of organs, cells and tissue. 67. The use of a cryoprotective agent, according to modality 66, in which said cryoprotectant has a weight average molecular weight (M w ) between 300 and 7,500 Da. 68. Use of a cryoprotection agent selected from the group consisting of isomalto-oligosaccharide and derivatives thereof that has a weight average molecular weight (Mw) between 300 and 1,650 Da, such as having an average molecular weight (Mw) between 850 and 1,650 Da, to cryopreserve a sample, in which said sample is selected from the group consisting of organs, cells and tissue. 69. The use of a cryoprotection agent, as defined in any of modalities 1 to 42, to cryopreserve a sample, such as a sample selected from the group consisting of organs, cells and tissue. 70. The use, according to any of the modalities 66 to 69, which comprises putting said sample to be cryopreserved in contact with said agent to obtain a cryopre composition 59/75 and subsequently reduce the temperature of the cryopreservation composition to a cryopreservation temperature. 71. Use of a cryopreservation composition, as defined in any of modalities 43 to 54, to cryopreserve a sample by reducing the temperature of said composition to a cryopreservation temperature. 72. The use, according to any of the modalities 66 to 71, in which the cryopreservation temperature is reached at a rate of 0.05 to 15, such as 0.1 to 10, such as 0.2 to 8, such as 0.3 to 6, such as 0.4 to 4, such as 0.5 to 2 ° C per minute. 73. The use, according to any of the modalities 66 to 72, in which the concentration of said cryoprotectant is from 4 to 20% by weight, as well as from 5 to 15% by weight, from 6 to 12% by weight, preferably from 6 to 10% by weight, or more preferably, from 7 to 9% by weight of cryoprotectant. 74. The use, according to any of modalities 66 to 73, in which the temperature of the sample in the cryopreservation composition is reduced to a temperature below - 50 ° C, such as between - 50 ° C to - 196 ° C , such as -80 ° C to -196 ° C. 75. The use, according to any of the modalities 66 to 74, in which the sample is thawed after cryopreservation. 76. The use, according to any of the modalities 66 to 75, in which said sample is functional after cryopreservation. 77. The use, according to any of the modalities 66 to 76, in which the sample to be cryopreserved is selected from the group consisting of organs, cells and tissues for transplantation. 78. The use, according to any of the modalities 66 to 77, p which is in a bank method, such as a method of mobilized peripheral blood bank, marrow bank method, adipose tissue bank method, a tissue bank method of 60/75 dental pulp, a breeding bank method or an umbilical cord bank method. 79. The use, according to any of the modalities 66 to 78, which is in a clinical bank method. [00137] All publications mentioned in the specification above are incorporated by reference in this document. Various modifications and variations of the described compositions, methods and systems of the present invention will be evident to those skilled in the art, without departing from the scope and spirit of the present invention. Although the present invention has been described in connection with specific preferred embodiments, it should be understood that the invention, as claimed, it should be understood that the invention, as claimed, should not be unnecessarily limited to such specific embodiments. Preparation Example 1 Isomalto-Oligosaccharide production 1 Hydrolysis of Low Molecular Weight Dextran [00138] 3345 kg of hydrolyzed dextran collected as permeate from a membrane with a cut-off value <5,000 Daltons, are hydrolyzed to pH 1.5 at a temperature of 95 ° C. [00139] Hydrolysis is monitored in a chromatographic manner using gel permeation chromatography (GPC), and is terminated by cooling when the molecular weight of the material that is hydrolyzed is estimated to have reached the desired value, that is, a weight average molecular weight of 850 to 1,150 Daltons. [00140] Through hydrolysis, low molecular weight isomalto-oligosaccharide is produced, but glucose is also formed. After cooling and neutralization, the amount of glucose and oligomers of very low molecular weight is reduced by membrane processes that have a cut-off value of 340 to 800 Daltons. After this process, 61/75 the isomalto-oligosaccharide content is determined, by optical rotation (at D 20 ~ 200), as being 915 kg, and the amount of reducing sugar is determined, using Somogyi's reagent, as being 22 , 5%. TABLE 1: RESULTS FROM THE GPC ANALYSIS. Number of glucose units in a molecule AUPW Relative AUPW Mi Contribution to Mw AUPN Relative AUPN Contribution to Mn 1 0.48 0.0028 180 1 0.0027 0.0130 2 2 5.94 0.0350 342 12 0.0174 0.0846 29 3 21.76 0.1282 504 65 0.0432 0.2103 106 4 28.3 0.1667 666 111 0.0425 0.2070 138 5 26.94 0.1587 828 131 0.0325 0.1585 131 6 22.58 0.1330 990 132 0.0228 0.1111 110 7 17.43 0.1027 1152 118 0.0151 0.0737 85 8 13.46 0.0793 1314 104 0.0102 0.0499 66 9 9.73 0.0573 1476 85 0.0066 0.0321 47 10 6.91 0.0407 1638 67 0.0042 0.0206 34 11 4.89 0.0288 1800 52 0.0027 0.0132 24 12 3.66 0.0216 1962 42 0.0019 0.0091 18 13 2.5 0.0147 2124 31 0.0012 0.0057 12 14 5.2 0.0306 2286 70 0.0023 0.0111 25169.78 1.00001020 0.2053 1.0000 827 AUPW: Area under peak (M w ) AUPN: Area under peak (Mn) [00141] As seen from Table 1 above, the isomaltooligosaccharide has an M W of 1,020 Da and M n equal to 827 Da, providing a polydispersion Pd = 1.23. Reducing sugar is measured as 22.5%. This isomalto-oligosaccharide is also called pentaisomaltose in this order. 62/75 Preparation Example 2 Production of Hydrogenated Isomalto-Oligosaccharide 1 [00142] After hydrolysis and fractionation, 418 kg of isomalto-oligosaccharide were left The reducing sugar was measured as 30.8%. This amount was treated with 10 kg of sodium borohydride and resulted in 362 kg of hydrogenated isomalto-oligosaccharide, before the final ion exchange. Henceforth, the solution was neutralized to pH <7.0, and subsequently deionized and finally spray dried. The reduction sugar of the final product was measured as 0.09%. TABLE 2: RESULTS FROM THE GPC ANALYSIS. Number of glucose units AUPW Relative AUPW Mi Contribution to M W AUPN Relative AUPN Contribution to Mn 1 0.31 0.0033 180 1 0.0017 0.0145 3 2 4.38 0.0472 342 16 0.0128 0.1076 37 3 14.55 0.1568 504 79 0.0289 0.2425 122 4 16.47 0.1775 666 118 0.0247 0.2077 138 5 14.65 0.1579 828 131 0.0177 0.1486 123 6 11.57 0.1247 990 123 0.0117 0.0982 97 7 8.61 0.0928 1152 107 0.0075 0.0628 72 8 6.57 0.0708 1314 93 0.0050 0.0420 55 9 4.77 0.0514 1476 76 0.0032 0.0271 40 10 3.43 0.0370 1638 61 0.0021 0.0176 29 11 2.43 0.0262 1800 47 0.0014 0.0113 20 12 1.76 0.0190 1962 37 0.0009 0.0075 15 13 1.19 0.0128 2124 27 0.0006 0.0047 10 14 2.11 0.0227 2286 52 0.0009 0.0078 1892.80 1.0000968 0.1190 1.0000 780 AUPW: Area under peak (M w ) AUPN: Area under peak (Mn) 63/75 [00143] As seen from table 2 above, the hydrogenated isomaltooligosaccharide has an M W of 968 Da and M n equal to 780 Da, providing a polydispersion Pd = 1.24. This hydrogenated isomaltooligosaccharide is also called a pentaisomaltoside in this application. Example 1 Preparation of Cryopreservation Agent [00144] The cryopreservation agent used in the following examples was prepared by aseptically solubilizing the cryoprotectant (such as DMSO, pentaisomaltose (isomalto-oligosaccharide 1) prepared as described in Preparation Example 1 or pentaisomaltoside (isomalt -hydrogenated oligosaccharide 1) prepared as described in Preparation Example 2) in growth medium (DMEM / F12 + 10% FBS + penicillin / streptomycin) to the final desired concentration (for example, for the 8% cryopreservation composition) isomalto-oligosaccharide 1, 8 grams to 100 ml of growth medium) and filtering the individual cryopreservation compositions. Example 2 Cryopreservation of Normal Human Dermal Fibroblasts (NHDF): [00145] NHDF (passage 2) were grown in conventional T flasks under standard conditions (37 ° C, 5% CO 2 and standard growth medium [DMEM / F12 + 10% FBS + penicillin / streptomycin)]). When the confluence reached (70 to 80%), the cell population was released from the flasks and centrifuged (1,000 rpm, 10 min). 0.5 x 10 6 cells were resuspended in six different cryopreserving agents (1 ml); 1) Growth medium + 10% DMSO, 2) Growth medium + 2% DMSO + 8% isomaltooligosaccharide 1, 3) Growth medium + 2% DMSO + 8% 64/75 hydrogenated isomalto-oligosaccharide 1, 4) Growth medium + 8% isomalto-oligosaccharide 1, 5) Growth medium + 8% hydrogenated isomalto-oligosaccharide 1 and 6) Growth medium without any additive (DMEM / F12 without FBS). The cells were then cryopreserved under standard controlled cryopreservation conditions using isopropanol-based methodology, freezing at a constant rate of 1 ° C / min until the temperature of liquid N2. After one week, the cells were thawed using a standard thawing protocol (immerse the conceptacle directly in a 37-degree water bath and transfer cell solution by dripping to the new growth medium at 37 ° C). The following analysis was done after thawing; 1) viability, using the equipment Nucleocounter (NC200), and 2) the first passage viability using Nucleocounter equipment (NC200). The results are shown in Figures 1 and 2 and summarized in tables 3 to 5. [00146] Viability after thawing is slightly reduced when using isomalto-oligosaccharide 1 as the only cryopreserving agent compared to the standard condition with the use of 10% DMSO. When 2% DMSO is used in conjunction with isomalto-oligosaccharide 1, no difference in viability is observed. The viability of cells cryopreserved with isomalto-oligosaccharide 1 alone in the 1st pass is similar to the standard conditions with the use of 10% DMSO. This experiment demonstrates that the cryopreservation of NHDF in a cryopreservation solution using isomalto-oligosaccharide 1 as the only cryoprotectant results in cultures that can be used in the same proportion as cultures from standard cryopreservation conditions. 65/75 Example 3 Cryopreservation of Normal Human Keratinocytes (NHEKS): [00147] NHEKs were cryopreserved using the same protocol as described in Example 2. The same experimental groups were included. The results are shown in Figure 3 to 4 and are summarized in Table 3 to 5. [00148] As also shown for NHDF, the results clearly demonstrate that NHEKs can be cryopreserved in a cryopreservation solution using isomaltooligosaccharide 1 as the only cryoprotectant. The viability in the first passage of the culture is at the same level as NHEKS cryopreserved under standard conditions with the use of 10% DMSO. Example 4 Cryopreservation of Normal Human Mesenchymal Stem Cells (HMSCS): [00149] hMSCs were cryopreserved using the same protocol as described in Example 2 with two more experimental groups included, growth medium + 8% isomaltooligosaccharide 1+ 2% trehalose and growth medium + 2% trehalose. The feasibility analysis was performed, using the Nucleocounter technique, as described above. The results are shown in Figure 5 and summarized in tables 3 to 5. [00150] The results clearly demonstrate that hMSCs can be cryopreserved in a cryopreservation solution with the use of Da isomalto-oligosaccharide as the only cryoprotectant. Viability after thawing is shown to be at the same level as the standard formulation containing 10% DMSO. 66/75 TABLE 3 TO 5: T1: SURVIVAL AFTER DEFROSTING T2: SURVIVAL AFTER 1 to PASS 10% DMSO NHDF NHEK hMSCT1 T2 T1 T2 T1 T2 10% DMSO 96 ± 5% 92 ± 2% 92 ± 3% 88 ± 5% 84 ± 10% AT 10% DMSO 98 ± 2% 95 ± 2% 75 ± 4% AT 90 ± 2% AT TABLE 3 NHDF NHEK hMSCsT1 T2 T1 T2 T1 T2 2% DMSO + 8% isomaltooligosaccharide 1 96 ± 5% 92 ± 2% 93 ± 2% 96 ± 1% 95 ± 1% AT 2% DMSO + 8% isomalto-hydrogenated oligosaccharide 1 98 ± 1% 96 ± 1% 81 ± 5% AT 90 ± 3 AT TABLE 4 NHDF NHEK hMSCT1 T2 T1 T2 T1 T2 8% isomalto-oligosaccharide 1 75 ± 5% 85 ± 5% 74 ± 1% 85 ± 8% 80 ± 7% AT 8% hydrogenated isomalto-oligosaccharide 1 82 ± 5% 90 ± 3% 85 ± 11% AT 80 ± 5 AT TABLE 5 EXAMPLE 5 Exposure of HMSCS to Isomalto-Oligosaccharide 1 [00151] hMSCs were grown until confluence in conventional T flasks. The cells were released and resuspended in two different formulations: 1) growth medium + 10% DMSO and 2) 8% isomalto-oligosaccharide 1. The final concentration of cells in each formulation was 1 x 10 6 / ml of cells . The same basic protocol as described in Example 2 was used. 1 ml from each conceptacle was added to cryotrips and the viability was analyzed using NucleoCounter at three different points in time; 1) 0 min. (T0), 10 min. (T10) and 30 min. (T30). The results are summarized in table 6. 67/75 T0 (%) T10 (%) T30 (%) 10% DMSO 100 67 41 8% isomalto-oligosaccharide 1 100 97 95 TABLE 6 [00152] It is clearly demonstrated that exposure to standard cryopreservation conditions seriously affects the viability of hMSCs. Exposure to cryoformulation with isomalto-oligosaccharide 1 as the only cryoprotectant component only affects viability significantly after exposure for 60 min. This demonstrates that it is possible to handle cell cultures for cryopreservation in the cryopreservation composition containing isomalto-oligosaccharide 1, making a greater number of flexible work procedures possible. EXAMPLE 6 Isomalto-Oligosaccharide 560 from HMSCS For Cryopreservation [00153] hMSCs were cryopreserved using the same basic protocol, as described in Example 2, and the same experimental groups were included. The results demonstrate that it is possible to cryopreserve hMSCs in 560 Da isomalto-oligosaccharide, however, hydrogenated 560 Da isomalto-oligosaccharide is not as effective as 560 Da isomalto-oligosaccharide in this experiment. The results are summarized in Table 7. 10%DMSO 8% isomaltooligosaccharide 560 Da + 2% DMSO 8% isomaltooligosaccharide 560 Da 8% hydrogenated isomaltooligosaccharide 560 Da + 2% DMSO 8% hydrogenated isomaltooligosaccharide 560 Da 90 ± 1% 66 ± 15% 78 ± 1% 60 ± 1% 44 ± 5% TABLE 7 EXAMPLE 7 HUMAN IPS CELLS IN PLURIPROLE GROWTH MEDIA [00154] The isomalto-oligosaccharide 1 used in this example is prepared as described in Preparation Example 1. Cells 68/75 human induced pluripotent stem, iPSCs, (passage 12) were grown in conventional T flasks as single cells under standard conditions (37 degrees, 5% CO 2 and PluriPro growth medium, Cell Guidance System). When reaching confluence (70 to 80%), the cell population was released from the flasks and centrifuged (1,000 rpm, 10 min). 0.5 x 10 6 cells were resuspended in twelve different cryopreservation solutions (1 ml); Growth medium + 10% DMSO, Growth medium + 5% DMSO, Growth medium + 10% DMSO + 2% isomalto-oligosaccharide 1, Growth medium + 10% DMSO + 4% isomalto-oligosaccharide 1, Growth medium + 10% DMSO + 8% isomaltooligosaccharide 1, Growth medium + 5% DMSO + 2% isomalto-oligosaccharide 1, Growth medium + 5% DMSO + 4% isomalto-oligosaccharide 1 , Growth medium + 5% DMSO + 8% isomalto-oligosaccharide 1, Growth medium + 2% isomalto-oligosaccharide 1, Growth medium + 4% isomaltooligosaccharide 1, Growth medium + 8% isomaltooligosaccharide 1, and Growth medium without any cryoprotectant. The cells were then cryopreserved under standard controlled cryopreservation conditions (using an isopropanol-based methodology) up to liquid N2. After one week, the cells were thawed using a standard thawing protocol (immerse the conceptacle directly in a 37-degree water bath and transfer the cell solution by dripping to new growth medium). The ROCK inhibitor was added under the first sowing. The feasibility analysis after thawing was performed, using the Nucleocounter technique. The results are shown in Figure 6. [00155] The results demonstrate that human iPS cells can be cryopreserved with the use of isomalto-oligosaccharide 1 as the only cryoprotectant, although the viability of the cryopreser cells 69/75 vadas is significantly less than the cases in which DMSO is added. EXAMPLE 8 HUMAN IPS CELLS IN PLURIPRO GROWTH MEDIUM [00156] The hydrogenated isomalto-oligosaccharide 1 used in this example is prepared as described in Preparation example 2. Human induced pluripotent stem cells, iPSCs, (cultured 12) were grown in flasks Conventional T as single cells under standard conditions (37 degrees, 5% CO 2 and PluriPro growth medium, Cell Guidance System). When reaching confluence (70 to 80%), the cell population was released from the flasks and centrifuged (1,000 rpm, 10 min). 0.5 x 10 6 cells were resuspended in twelve different cryopreservation solutions (1 ml); Growth medium + 10% DMSO, Growth medium + 5% DMSO, Growth medium + 10% DMSO + 2% hydrogenated isomalto-oligosaccharide 1, Growth medium + 10% DMSO + 4% isomalto- hydrogenated oligosaccharide 1, Growth medium + 10% DMSO + 8% hydrogenated isomalto-oligosaccharide 1, Growth medium + 5% DMSO + 2% hydrogenated isomalto-oligosaccharide 1, Growth medium + 5% DMSO + 4 % hydrogenated isomaltooligosaccharide 1, growth medium + 5% DMSO + 8% hydrogenated isomalto-oligosaccharide 1, growth medium + 2% hydrogenated isomalto-oligosaccharide 1, growth medium + 4% hydrogenated isomalto-oligosaccharide 1, Growth medium + 8% hydrogenated isomalto-oligosaccharide 1 and Growth medium without any cryoprotectant. The cells were then cryopreserved under standard controlled cryopreservation conditions (using an isopropanol-based methodology) up to liquid N2. After one week, the cells were thawed using a standard thawing protocol (immersing the conceptacle directly in a bath 70/75 water, 37 degrees and transfer cell solution by drip to new growth medium). The ROCK inhibitor was added under the first sowing. The feasibility analysis after thawing was performed, using the Nucleocounter technique. The results are shown in Figure 7. [00157] The results demonstrate that human iPS cells can be cryopreserved with the use of hydrogenated isomalto-oligosaccharide 1 with the only cryoprotectant, although the viability of the cryopreserved cells is significantly less than the cases in which DMSO is added. In cryopreserved samples without DMSO, a trend towards improved viability as a function of the used isomalto-oligosaccharide concentration 1 was observed. EXAMPLE 9 CRYOPRESERVATION OF NORMAL HUMAN MESENQUIMAL STEM CELLS (HMSCS) IN CRYOPROTECTORS WITH DIFFERENT MOLECULAR WEIGHTS: [00158] hMSCs were cryopreserved using the same protocol as described in Example 2 which involves the following experimental groups, growth medium + 10% DMSO, 8% isomaltooligosaccharide 1, average Dextran Mw 10,000 or average Dextran Mw 40,000 + 5 % DMSO, 8% isomalto-oligosaccharide 1, Dextran Mw average 10,000 or Dextran Mw average 40,000 + 1% DMSO, 8% isomalto-oligosaccharide 1, Dextran Mw average 10,000 or Dextran Mw medium 40,000 and growth medium. The feasibility analysis was performed, using the Nucleocounter technique as described above. After thawing, MSCs were cultured for 3 days under standard conditions and the proliferative rate was analyzed using in vitro colorimetric analysis, the MTT assay that measures mitochondrial activity in a cell population. [00159] The results are shown in Figure 8. 71/75 [00160] The results clearly demonstrate that hMSCs can be cryopreserved in a cryopreservation solution using isomalto-oligosaccharide 1, Dextran Mw average 10,000 or Dextran Mw average 40,000 with the only cryoprotectant. No significant difference was observed between Mw on the direct feasibility analysis after thawing. However, analysis of the proliferative rate after 3 days demonstrated that cryopreserved hMSCs in 8% isomaltooligosaccharide 1 (average Mw 1,000) proliferated more actively compared to 8% average Dewtran Mw 10,000 and average Mw 40,000. EXAMPLE 10 CRYOPRESERVATION OF NORMAL HUMAN MESENCHYMAL STEM CELLS (HMSCS) IN ISOMALTOOLIGOSACARID WITH A MEDIUM MW OF 1,500 MW: [00161] The hMSCs were cryopreserved using the same protocol as described in Example 2 which involves the following experimental groups, growth medium + 10% DMSO, growth medium + 2% DMSO, 8% isomalto-oligosaccharide that has an average Mw of 1,500 Mw + 2% DMSO, 8% isomalto-oligosaccharide which has an average Mw of 1,500 Mw and growth medium. The feasibility analysis was performed, using the Nucleocounter technique as described above. The results are shown in Figure 9. [00162] The results clearly demonstrate that hMSCs can be cryopreserved in a cryopreservation solution using isomalto-oligosaccharide that has an average Mw of 1,500 as the only cryoprotectant. EXAMPLE 11 [00163] The viability of CD34 + hematopoietic stem cell after cryopreservation with DMSO, isomalto-oligosaccharide 1 or hydrogenated isomaltooligosaccharide 1. 72/75 [00164] The mobilized peripheral blood cells were collected by leukapheresis and frozen in cryoprotectant medium containing 10% DMSO or different concentrations of hydrogenated isomaltooligosaccharide 1 (isom) or hydrogenated isomalto-oligosaccharide 1 (h-isom). The samples were frozen using a controlled rate freezer (Kryo 560-16, Planer; initial temperature 4 ° C, 1 ° C / min. To 0 ° C, -2 ° C / min. To -45 ° C and -5 ° C / min to -100 ° C) and moved to -150 ° C. The samples were thawed in a 37 ° C water bath. Flow cytometry was applied to estimate the viability of CD45 +, CD34 + hematopoietic stem cells. The fluorescent DNA binding compound 7-Aminoactinomycin D (7AAD) was used as a live / dead marker. Cells capable of excluding 7AAD were considered to be viable. The results are shown in Figure 10: Isomalto-oligosaccharide 1 (light gray bars), hydrogenated isomalto-oligosaccharide 1 (dark gray bars) and DMSO (black bars). The data shown here are from 3 separate experiments, each measured in duplicate. The error bars indicate the standard deviation. [00165] Both h-isom and isom support the viability of CD34 + hematopoietic cells after cryopreservation to the same extent as the 10% DMSO standard. An evident trend towards a superior protective effect with higher concentrations of both i-sound and isom is demonstrated. Concentrations of 4% have a significantly lower protective effect (below 60%) than concentrations of 6%, 8%, 10% and 12%. Concentrations of 10% and 12% have a similar protective effect compared to 10% DMSO. No significant difference between the protective effects of h-isom and isom was observed in the study. 73/75 EXAMPLE 12 ADIPOSE DERIVATIVE STEM CELLS / STROMAL VIABILITY (ASC'S) AFTER CRYOPRESERVATION WITHOUT DMSO, ISOMALTO-OLIGOSACARIDE 1 OR HYDROGENED ISOMALTOOLIGOSACARIDE 1. [00166] ASCs were collected from adipose tissue obtained by cosmetic liposuction of the abdomen or groin using the Vibrasat device (Moller Medical GmbH & Co. KG, Fulda, Germany). ASC's from the stromal vascular fraction were expanded ex vivo in culture medium consisting of Eagle medium modified by Dulbecco, 1% penicillin-streptomycin, 1% GlutaMAX and 10% clustered human platelet lysate. The cells were frozen in cryoprotectant medium containing 10% DMSO or different concentrations of hydrogenated isomalto-oligosaccharide 1 (isom) or hydrogenated isomalto-oligosaccharide 1 (h-isom). The samples were frozen using a controlled rate freezer (Kryo 560-16, Planer; initial temperature 4 ° C, -1 ° C / min to 0 ° C, -2 ° C / min to -45 ° C and -5 ° C / min to -100 ° C) and moved to -150 ° C. The samples were chilled in a 37 ° C water bath. Flow cytometry was applied to characterize the phenotype (positive for CD73, CD90, CD105 and negative for CD14, CD20, CD45 and CD34) and to estimate the viability of ASC's. The fluorescent DNA binding compound 7Aminoactinomycin D (7-AAD) was used as a live / dead marker. Cells capable of excluding 7AAD were considered to be viable. The results are shown in Figure 11: Isomaltooligosaccharide 1 (light gray bars), hydrogenated isomalto-oligosaccharide 1 (dark gray bars) and DMSO (black bars). The data shown here are from a single experiment measured in duplicate. The error bars indicate the standard deviation. The result for DMSO is less than expected. 74/75 [00167] Both h-isom and isom and cryoprotectants support the viability of ASCs to the same extent as 10% DMSO. Except for the low concentration of 4%, higher concentrations result in a viability above 70%. A concentration of 12% results in significantly greater viability (80% to 90%) compared to lower concentrations. No significant difference between the cryoprotective effects of h-isom and isom was observed in the study, except for the 4% group. EXAMPLE 13 [00168] After removing mouse ovaries, they are transferred to a McCoy medium supplemented with 10 mg / ml HSA, pen / strep. and maintained at 37 ° C until transferred to cryopreservation solutions below: 1) standard conditions (PBS, 1.5 mol / l ethylene glycol, 0.1 mol / l sucrose, 10 mg / ml similar HSA cryopreservation of human ovarian tissue) or 2) with PBS, 10% (weight by volume) of isomalto-oligosaccharide 1. [00169] The ovaries are balanced for 30 min on ice and then transferred to a programmable cryo-freezer (programmable freezer Planner Cryo 10, UK), where the samples are cooled to -140 ° C with the following ramps (initial temperature : - 1 ° C; - 2 ° C / min to -9 ° C; retention 5 min; seeding; -0.3 ° C / min to - 40 ° C, -10 ° C / min to -140 ° C and then directly into liquid nitro genius). After that, they are dipped in liquid nitrogen and kept in a liquid nitrogen tank for a variable period of time. Defrosting: room temperature in hot water at 37 ° C; 10 min an isomalto-oligosaccharide 1 medium (20% (weight by volume) and then directly in fixation medium. In histological preparations, both ovaries show surviving follicles at different stages of development. 75/75 EXAMPLE 14 [00170] Mouse ovaries are treated as described in Example 13 above, but in the cryopreservation solutions below: 1) standard conditions (PBS, 1.5 mol / l ethylene glycol, 0.1 mol / l of sucrose, 10 mg / ml of HSA similar to the cryopreservation of human ovarian tissue) or 2) with PBS, 1.5 mol / l of ethylene glycol, 10 mg / ml of HSA, 10% (weight by volume) of isomalto- hydrogenated oligosaccharide 1 or 3) with PBS, 10 mg / ml HSA, 10% (weight by volume) hydrogenated isomaltooligosaccharide 1. In histological preparations, all ovaries show surviving follicles at different stages of development.
权利要求:
Claims (26) [1] 1. Use of a cryoprotection agent, characterized by the fact that it is to cryopreserve a sample, in which said sample is selected from the group consisting of mammalian organs, mammalian cells and mammalian tissues, in which said cryoprotective agent comprises a cryoprotectant being one or more of: dextrin, dextran, isomaltooligosaccharide, and derivatives thereof, such derivative is selected from the group consisting of hydrogenated isomalto-oligosaccharide, hydrogenated dextran, hydrogenated dextrin, oxidized oxide, oxide oxide, oxide oxide , oxidized dextrin, DEAEdextrin, DEAE-dextran, DEAE-isomalto-oligosaccharides, C1-10-dextrin carboxyalkyl, C1-w-dextran carboxyalkyl and C1-10isomalto-oligosaccharide carboxyalkyl; and (a) wherein said cryoprotection agent comprises at least 1% by weight of one or more isomalto-oligosaccharides and derivatives thereof having a weight average molecular weight (Mw) between 300 and 1,650 Da based on the total weight of dextrin, dextran, isomalto-oligosaccharide and derivatives thereof in said cryoprotectant, or (b) wherein said cryoprotectant has a weight average molecular weight (Mw) between 300 and 9,500 Da. [2] 2. Use, according to claim 1, characterized by the fact that said cryoprotection agent comprises at least 1% by weight of one or more isomalto-oligosaccharides and derivatives thereof having a weight average molecular weight (Mw) between 300 and 1,650 Da based on the total weight of dextrin, dextran, isomaltooligosaccharide and derivatives thereof in said cryoprotection agent. [3] 3. Use according to claim 1 or 2, characterized Petition 870190064769, of 10/07/2019, p. 7/16 2/6 due to the fact that said cryoprotectant has an average molecular weight (Mw) between 500 and 3,500 Da. [4] 4. Use according to any one of claims 1 to 3, characterized by the fact that said cryoprotectant is selected from the group consisting of isomalto-oligosaccharide and derivatives thereof and has a weight average molecular weight (Mw) between 850 and 1,650 Da. [5] 5. Use according to any one of claims 1 to 4, characterized by the fact that said cryoprotectant has a polydispersion of> 1 and <5. [6] 6. Use according to any one of claims 1 to 5, characterized by the fact that said cryoprotectant is isomaltooligosaccharide having a weight average molecular weight (Mw) between 850 and 1,150 Da. [7] 7. Use according to any one of claims 1 to 6, characterized by the fact that said cryoprotectant is hydrogenated isomaltooligosaccharide that has a weight average molecular weight (Mw) between 850 and 1,150 Da. [8] 8. Use according to claim 6 or 7, characterized by the fact that the weight fraction of isomalto-oligosaccharides that has less than 3 glucose units is less than 15% by weight and / or in which the fraction of weight of isomalto-oligosaccharides that have more than 9 glucose units is less than 20% by weight. [9] Use according to any one of claims 1 to 8, characterized by the fact that said isomalto-oligosaccharides and derivatives thereof are based on dextran. [10] 10. Use according to any one of claims 1 to 9, characterized in that said agent is in the form of a powder or in the form of a solution. [11] 11. Use according to any one of claims 1 Petition 870190064769, of 10/07/2019, p. 8/16 3/6 to 10, characterized by the fact that said agent comprises from 30% to 70% by weight of said cryoprotectant. [12] 12. Use according to any one of claims 1 to 11, characterized in that said cryoprotectant agent comprises at least one additional cryoprotectant selected from the group consisting of acetamide, agarose, alginate, 1-analine, albumin, ammonium acetate, butanediol, chondroitin sulfate, chloroform, choline, diethylene glycol, dimethyl acetamide, dimethyl formamide, dimethyl sulfoxide (DMSO), erythritol, ethanol, ethylene glycol, formamide, glucose, glycerol, a-glycerophosphate, monoacetate glycerol, glycine, hydroxyethyl starch, inositol, lactose, magnesium chloride, magnesium sulfate, maltose, mannitol, mannose, methanol, methyl, acetamide, methylformamide, methyl ureas, phenol, pluronic polyols, polyethylene glycol, polyvinylpyrrolidone, propoline glycol, pyridine N-oxide, ribose, serine, sodium bromide, sodium chloride, sodium iodide, sodium nitrate, sodium sulfate, sorbitol, sucrose, trehalose, triethylene glycol, trimethyl acetate amine, urea, valine and xylose. [13] Use according to any one of claims 1 to 12, characterized in that the sample is selected from the group consisting of mammalian organs, mammalian cells, and mammalian tissues from a human. [14] 14. Use according to any one of claims 1 to 13, characterized by the fact that said sample are cells selected from the group consisting of hematopoietic stem cells, mesenchymal stem cells, embryonic stem cells and IPS cells , or in which said sample is blood cells, or in which said sample is ovarian tissue. [15] 15. Use according to any one of claims 1 to 14, characterized by the fact that said sample is hematopoietic stem cells. Petition 870190064769, of 10/07/2019, p. 9/16 4/6 [16] 16. Use according to any one of claims 1 to 14, characterized by the fact that said sample is blood cells. [17] 17. Use of a cryoprotection agent, characterized by the fact that it is to cryopreserve a sample, in which said sample is selected from the group consisting of hematopoietic stem cells, mesenchymal stem cells, embryonic stem cells and cells IPS, or in which said sample is blood cells, or in which said sample is ovarian tissue, in which said cryoprotection agent comprises a cryoprotectant being one or more of dextrin, dextran, isomaltooligosaccharide, and derivatives thereof, such derivative is selected from the group consisting of hydrogenated isomalto-oligosaccharide, hydrogenated dextran, hydrogenated dextrin, oxidized isomaltooligosaccharide, oxidized dextran, oxidized dextrin, DEAEdextrin, DEAE-dextran, DEAE-isoxycarboxyl, carboxyl-oligosaccharide-oligosaccharide-carboxyl-oligosaccharide C1-w-dextran and C1-10isomalto-oligosaccharide carboxyalkyl; and (a) in which said cryoprotection agent comprises at least 1% by weight of one or more among isomalto-oligosaccharides and derivatives thereof having a weight average molecular weight (Mw) between 300 and 1,650 Da based on the total weight of dextrin, dextran, isomalto-oligosaccharide and derivatives thereof in said cryoprotection agent, and (b) wherein said cryoprotectant has a weight average molecular weight (Mw) between 300 and 9,500 Da. [18] 18. Use according to any one of claims 1 to 17, characterized by the fact that said dextrin, dextran, isomaltooligosaccharide, or a derivative thereof, is the only cryoprotectant in the cryoprotective agent. Petition 870190064769, of 10/07/2019, p. 10/16 5/6 [19] 19. Cryoprotective agent, characterized by the fact that it comprises a cryoprotectant being one or more of dextrin, dextran, isomalto-oligosaccharide, and derivatives thereof, such derivative is selected from the group consisting of hydrogenated isomalto-oligosaccharide, hydrogenated dextran , hydrogenated dextrin, oxidized isomaltooligosaccharide, oxidized dextran, oxidized dextrin, DEAEdextrin, DEAE-dextran, DEAE-isomalto-oligosaccharides, carboxyalkyl C1-10-dextrin, carboxyalkyl C1-w-dextran; and (a) in which said cryoprotection agent comprises at least 1% by weight of one or more among isomalto-oligosaccharides and derivatives thereof having a weight average molecular weight (Mw) between 300 and 1,650 Da based on the total weight of dextrin, dextran, isomalto-oligosaccharide and derivatives thereof in said cryoprotection agent, or (b) wherein said cryoprotectant has a weight average molecular weight (Mw) between 300 and 9,500 Da. [20] 20. Cryoprotective agent, characterized by the fact that it comprises a cryoprotectant selected from the group consisting of isomalto-oligosaccharide and derivatives thereof, such a derivative is selected from the group consisting of hydrogenated isomaltooligosaccharide, an oxidized isomalto-oligosaccharide, DEAE-isomalto-oligosaccharides, a C1-10-isomaltooligosaccharide carboxyalkyl and an oxidized C1-10-isomaltooligosaccharide carboxyalkyl, which has a weight average molecular weight (Mw) between 300 and 1,650 Da. [21] 21. Cryopreservation composition, characterized by the fact that it comprises a cryoprotection agent, as defined in any one of claims 1 to 20, and whose cryopreservation composition additionally comprises a sample to be cryopreserved Petition 870190064769, of 10/07/2019, p. 11/16 6/6 served, wherein said sample is selected from the group consisting of mammalian organs, mammalian cells and mammalian tissues. [22] 22. Cryopreservation composition according to claim 21, characterized by the fact that said sample is as defined in any one of claims 13 to 16. [23] 23. Cryopreservation composition according to claim 21 or 22, characterized in that it comprises said cryoprotectant in an amount of 1 to 50% by weight. [24] 24. Cryopreservation composition according to any one of claims 21 to 23, characterized in that it comprises DMSO in an amount of 1 to 5% by weight. [25] 25. Method for cryopreserving a sample, characterized by the fact that it comprises the steps of placing a sample that is cryopreserved in contact with a cryoprotection agent, as defined in any one of claims 1 to 20, to obtain a cryopreservation composition and subsequently reducing the temperature of the cryopreservation composition to a cryopreservation temperature, wherein said sample is selected from the group consisting of mammalian organs, mammalian cells and mammalian tissues. [26] 26. Method according to claim 24, characterized by the fact that said sample is as defined in any one of claims 13 to 16.
类似技术:
公开号 | 公开日 | 专利标题 BR112015012161B1|2020-05-05|cryoprotection agent and its use, cryoprotection compositions and method for cryopreserving sample ". CN104145943B|2016-02-17|A kind of frozen protection liquid of people's umbilical cord China Tong Shi glue tissue and preparation and application thereof Rao et al.2015|Nanoparticle-mediated intracellular delivery enables cryopreservation of human adipose-derived stem cells using trehalose as the sole cryoprotectant CN109090100A|2018-12-28|A kind of mesenchymal stem cell cryopreserving liquid and preparation method thereof and application method JP2012533620A|2012-12-27|Methods and compositions for improving the viability of cryopreserved cells US20180325100A1|2018-11-15|Cryopreservative Compositions And Methods Of Use Thereof BR112021005257A2|2021-06-15|method for obtaining an enriched population of functional mesenchymal stem cells, cells obtained from them and compositions comprising them WO2015150394A1|2015-10-08|Cryoprotective agent, cryoprotective and cryopreserved compositions, uses thereof, and methods of cryopreservation ES2871373T3|2021-10-28|Cryoprotective agent, cryoprotective and cryopreserved compositions, their uses and cryopreservation methods JP2016059290A|2016-04-25|Vitrification cryopreservation method for animal cells US10765111B1|2020-09-08|Cryosolutions and uses thereof JP6475242B2|2019-02-27|Boron-added cell cryopreservation medium JP2019033707A|2019-03-07|Vitrification freezing preservation liquid and vitrification freezing preservation method TWI681955B|2020-01-11|Application of compatible solute frozen cell preservation composition to human hematopoietic stem cells US20200396985A1|2020-12-24|Preservation and cryopreservation media JP7038369B2|2022-03-18|Composition for cryopreservation of bovine germ cells and cryopreservation method CN112106765A|2020-12-22|Stem cell protection solution and stem cell preservation method CN113735989A|2021-12-03|Trehalose derivative and cryoprotectant and application thereof Koschiy et al.2012|Protective Effect of Methylcellulose during Cryopreservation of Inoculated Cells in Serum-Free Medium
同族专利:
公开号 | 公开日 JP2019004904A|2019-01-17| KR102196974B1|2020-12-31| AR093662A1|2015-06-17| JP6438887B2|2018-12-19| ZA201503397B|2017-05-31| CA2891198A1|2014-06-05| EP3925443A4|2021-12-22| CN104918486B|2017-12-15| CN104918486A|2015-09-16| CN108112575B|2021-09-10| EA028147B1|2017-10-31| BR112015012161A8|2019-10-01| EP2934109B1|2021-03-03| MX370136B|2019-12-03| AU2013351058A1|2015-05-28| IL239027A|2018-10-31| CN108112575A|2018-06-05| JP6978644B2|2021-12-08| JP2021192625A|2021-12-23| IL239027D0|2015-07-30| KR20150095723A|2015-08-21| MX2015006617A|2015-12-16| AU2013351058B2|2017-03-16| SG11201504116SA|2015-06-29| EP2934109A1|2015-10-28| EA201591052A1|2015-09-30| JP2016501873A|2016-01-21| EP3925443A1|2021-12-22| US20150320031A1|2015-11-12| BR112015012161A2|2017-07-11| WO2014083169A1|2014-06-05|
引用文献:
公开号 | 申请日 | 公开日 | 申请人 | 专利标题 JPH0160441B2|1982-11-01|1989-12-22|Taiyo Sanso Co Ltd| JPS6261321B2|1983-12-15|1987-12-21|Fujirebio Kk| CA2128527A1|1992-01-21|1993-07-22|Raymond P. Goodrich, Jr.|Method of freezing cells and cell-like materials| JP3509148B2|1993-10-07|2004-03-22|明治製菓株式会社|Frost protection agent and cryopreservation method| US5629145A|1995-03-24|1997-05-13|Organ, Inc.|Cryopreservation of cell suspensions| JPH09110601A|1996-09-05|1997-04-28|Biosurface Technol Inc|Cryopreservation of cultured epithelial cell sheet| DK173138B1|1998-11-20|2000-02-07|Pharmacosmos Holding As|Process for Preparing an Iron Dextran Compound, Iron Dextran Compound Prepared by the Process, Pharmaceutical| KR100324351B1|1998-11-25|2002-11-18|박관화|Cryoprotectant comprising fructooligosaccharides, isomaltooligosaccharides, or galactooligosaccharides| JP2000201672A|1999-01-11|2000-07-25|Asahi Medical Co Ltd|Composition for cryopreservation of nucleated cell| EP1475434A1|2003-05-09|2004-11-10|Oncoscience AG|Method for storing tumor cells| CN101215338B|2007-01-05|2010-09-15|庄茅|Iron isomaltum oligosaccharide and preparing method thereof| CA2688504A1|2007-06-18|2008-12-24|Children's Hospital & Research Center At Oakland|Method of isolating stem and progenitor cells from placenta| EP3172963B1|2008-08-20|2019-02-06|Celularity, Inc.|Improved cell composition and methods of making the same| CN102132697B|2010-01-21|2013-08-21|周海华|Amniotic membrane long-term preserving fluid and preparation method thereof| WO2011143741A1|2010-05-15|2011-11-24|Hopital Maisonneuve-Rosemont|Extenders for mammalian sperm processing and preservation| GB201117469D0|2011-10-10|2011-11-23|Cell Guidance Systems Ltd|Culture media for pluripotent stem cells|CN101365458B|2006-01-06|2012-09-05|卢特波尔德药品公司|Methods and compositions for administration of iron| RS55700B1|2009-03-25|2017-07-31|Pharmacosmos Holding As|A stable iron oligosaccharide compound| EP2885969B1|2013-12-19|2018-06-27|FertiPro N.V.|Cryopreservation tools and methods| WO2015150394A1|2014-04-01|2015-10-08|Pharmacosmos A/S|Cryoprotective agent, cryoprotective and cryopreserved compositions, uses thereof, and methods of cryopreservation| US20170336399A1|2014-11-14|2017-11-23|Yale University|Novel methods and devices for high-throughput quantification, detection and temporal profiling of cellular secretions, and compositions identified using same| US20170303530A1|2014-11-14|2017-10-26|Japanese Red Cross Society|Method and solution for cryopreservation of umbilical cord blood and peripheral blood| TWI548748B|2015-04-16|2016-09-11|台灣尖端先進生技醫藥股份有限公司|Method of ex vivo expanding hematopoietic stem/progenitor cells and the composition produced thereby| CN108934158A|2016-02-01|2018-12-04|Gc细胞治疗|Cell cryopreservation culture media composition and its application| JP6932893B2|2016-03-16|2021-09-08|一般社団法人家畜改良事業団|Diluted solution for sperm and storage method of sperm using it| CN106085996A|2016-06-17|2016-11-09|上海理工大学|Complex stabilizer and add the enzyme activity determination method of NMN transferring enzyme of this complex stabilizer| US20190183910A1|2016-06-23|2019-06-20|Kutluk Oktay|Enhancing dna repair and preventing aging and its consequences in reproductive and other cells| CN106177918A|2016-09-30|2016-12-07|广州赛莱拉干细胞科技股份有限公司|A kind of mesenchymal stem cell injection and its preparation method and application| WO2018110159A1|2016-12-14|2018-06-21|株式会社大塚製薬工場|Mammalian cell cryopreservation liquid| KR20180088071A|2017-01-26|2018-08-03|중앙대학교 산학협력단|Composition for cryopreservating spermatogonial stem cells containing melatonin and method of cryopreservation of spermatogonial stem cells using same| KR20180088068A|2017-01-26|2018-08-03|중앙대학교 산학협력단|Composition for cryopreservating spermatogonial stem cells containing necrostatin-1 and method of cryopreservation of spermatogonial stem cells using same| CN106821938B|2017-03-21|2020-03-24|北京海康殷氏生物科技有限责任公司|Preparation method of human mesenchymal stem cell freeze-dried powder| CN106908294A|2017-03-24|2017-06-30|漯河医学高等专科学校|A kind of processing method of Pathologic specimen| EP3403502A1|2017-05-17|2018-11-21|Association For The Advancement Of Tissue Engineering and Cell Based Technologies|Cryoprotectant and/or cryopreservant composition, methods and uses thereof| JP2019110799A|2017-12-22|2019-07-11|三菱製紙株式会社|Vitrification freezing preservation method of animal cell| CN108018210B|2017-12-30|2020-11-06|华中农业大学|Preservation method of salmonella choleraesuis vaccine strain and special protective agent thereof| CN108371207A|2018-01-23|2018-08-07|浙江海洋大学|A kind of freezing prawn pre-treatment reagent and application method| CN109362708A|2018-11-15|2019-02-22|广州南医大生物工程有限公司|A kind of stem cell refrigerant and its application| KR102150120B1|2018-11-26|2020-09-01|대한민국|Composition for freeze-drying of microorganisms| CN110241027B|2019-07-17|2021-07-13|厦门昶科生物工程有限公司|Preservation method of Isochrysis galbana| WO2021016575A1|2019-07-24|2021-01-28|Board Of Regents, The University Of Texas System|Cryoprotectant polymers and methods of making and using thereof| KR102058338B1|2019-08-05|2019-12-23|충남대학교 산학협력단|Composition for cryopreservation of Canidae sperm comprising mesenchymal stem cell as effective component| RU2731065C1|2019-12-24|2020-08-28|Федеральное государственное бюджетное учреждение науки Институт биологии развития им. Н.К. Кольцова РАН |Cryopreservant composition for long-term storage of primary keratinocytes| RU2744614C1|2020-02-25|2021-03-11|Федеральное государственное бюджетное учреждение науки "Кировский научно-исследовательский институт гематологии и переливания крови Федерального медико-биологического агентства"|Method for reducing toxicity of cryopreservation solution based on dimethyl sulfoxide after thawing of hematopoietic stem cells| CN111345282A|2020-03-17|2020-06-30|广东万海细胞生物科技有限公司|Cell cryopreservation liquid and cryopreservation method| CN111280166A|2020-04-08|2020-06-16|广州裕康生物科技有限公司|Vitrification refrigerating fluid and freezing method of blastocyst| CN113287599A|2021-04-30|2021-08-24|创芯国际生物科技有限公司|Cryopreservation liquid composition, cryopreservation liquid and organoid cryopreservation method|
法律状态:
2018-03-06| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]| 2018-03-13| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]| 2018-03-20| B06I| Publication of requirement cancelled [chapter 6.9 patent gazette]|Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. | 2019-05-14| B06T| Formal requirements before examination [chapter 6.20 patent gazette]| 2020-02-27| B09A| Decision: intention to grant [chapter 9.1 patent gazette]| 2020-05-05| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/11/2013, OBSERVADAS AS CONDICOES LEGAIS. | 2021-11-03| B25A| Requested transfer of rights approved|Owner name: PHARMACOSMOS HOLDING A/S (DE) |
优先权:
[返回顶部]
申请号 | 申请日 | 专利标题 US201261731849P| true| 2012-11-30|2012-11-30| EP12195033|2012-11-30| US201261740211P| true| 2012-12-20|2012-12-20| EP12198598|2012-12-20| EP13180869|2013-08-19| PCT/EP2013/075128|WO2014083169A1|2012-11-30|2013-11-29|Cryoprotecting agent, cryoprotecting and cryopreserved compositions, uses thereof, and methods of cryopreservation| 相关专利
Sulfonates, polymers, resist compositions and patterning process
Washing machine
Washing machine
Device for fixture finishing and tension adjusting of membrane
Structure for Equipping Band in a Plane Cathode Ray Tube
Process for preparation of 7 alpha-carboxyl 9, 11-epoxy steroids and intermediates useful therein an
国家/地区
|